LOS ANGELES, CA–(Marketwire – July 12, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mymedicalrecords.com) today announced it has entered into an agreement with Benchmark Financial Groups to help fund the Company’s deployment of MMRPro, including the specially configured Kodak 520MDPro scanner designed exclusively for distribution with the MMRPro system. MMRPro is the Company’s complete end-to-end electronic document and patient record chart management system designed to provide healthcare professionals with an easy-to-use and cost-effective solution to digitize, store, retrieve and electronically share medical records (www.mmrmdvideos.com).

Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer, said, “This credit facility is designed to ensure the Company can maintain sufficient inventories of Kodak 520MDPro scanners and Capture Pro software to support Kodak’s domestic and international sales teams, the recently announced sales agreement with National Payment Providers (NPP), and the Company’s direct sales efforts without the need to use the Company’s existing credit line with The RHL Group or its pending equity line. NPP currently sells billing services to more than 168,000 healthcare clients and will offer MMRPro as part of its services.” 

“This program will also provide the resources necessary to expand the Company’s training, installation and customer support personnel for MMRPro Services,” Lorsch added.

MMRGlobal, Inc. is headquartered in Los Angeles, California. In addition to the MMRPro solution for healthcare professionals, the Company’s suite of information technology products includes the MyMedicalRecords Personal Health Record and MyEsafeDepositBox electronic vault. To view demonstrations of the Company’s products, visit www.mmrtheatre.com. 

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheatre.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the healthcare community, risks related to the current uncertainty and instability in financial and lending markets, timing and volume of sales and installations, length of sales cycles and the installation process, market acceptance of new product introductions, ability to establish and maintain strategic relationships, ability to identify and integrate acquisitions, relationships with licensees, competitive product offerings and promotions, compliance with and changes in government laws and regulations and future changes and initiatives in the healthcare industry, undetected errors in our products, risks related to third party vendors, risks related to obtaining and integrating third-party licensed technology, acceptance of the Company’s marketing and promotional campaigns, risks related to a security breach by third parties, maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets, uncertainties associated with doing business internationally across borders and territories, and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. 

Click here to see all recent news from this company

SCOTTSDALE, AZ–(Marketwire – July 12, 2010) –  Rural/Metro Corporation (NASDAQ: RURL) announced today that senior human resources executive Maureen Thompson, 49, has joined the Company to lead strategic and corporate human resources throughout the enterprise.

Michael P. DiMino, President and Chief Executive Officer, said, “Maureen is a highly regarded human resources leader with an extensive record of strategic and operational experience in large organizations across a variety of industries. She is a results-driven, operationally motivated leader who is adept at communication and collaboration at every level of an organization. We are very pleased to welcome her to Rural/Metro.”

In her role at Rural/Metro, Ms. Thompson will be responsible for all human resources leadership, strategy and direction, including employee relations, training, recruiting, compensation, benefits, organizational management, and policy and procedure development. She will report directly to the CEO.

Ms. Thompson has a demonstrated track record of working with large consumer product and retail organizations, including Retail HR Strategic Business Partner for The Goodyear Tire and Rubber Company, the world’s largest tire company with annual sales of $18 billion, from 2006 to 2009. From 2002 to 2006, she was Vice President of Human Resources for LESCO Inc., a $585 million public company that was the nation’s largest distributor of landscape and lawn care products (now an operating company of John Deere). Prior to that, Ms. Thompson was Vice President of Human Resources for Alamo Local Market Division, a division of ANC Retail Corporation, from 2000 to 2002.

“I am excited about this great opportunity and look forward to building a best-in-class human resources team that focuses on both strategic and tactical solutions that will support Rural/Metro’s organizational growth in the future,” Ms. Thompson said.

About Rural/Metro

Rural/Metro Corporation provides emergency and non-emergency ambulance services and private fire protection services in 20 states and approximately 400 communities throughout the United States. For more information, visit the Company’s web site at www.ruralmetro.com.

SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS

The foregoing reflects the Company’s views about its future financial condition, performance and other matters that constitute “forward-looking” statements as such term is defined by the federal securities laws. Many of these statements can be found by looking for words such as “believe,” “anticipate,” “expect,” “plan,” “intend,” “may,” “should,” “will likely result,” “continue,” “estimate,” “project,” “goals,” or similar words used herein in connection with any discussions of future operating or financial performance or business prospects. We may also make forward-looking statements in our earnings reports filed with the Securities and Exchange Commission, earnings calls and other investor communications. These forward-looking statements are subject to the safe harbor protection provided by federal securities laws. These forward-looking statements are subject to numerous risks, uncertainties and assumptions, including those relating to the Company’s future business prospects, future growth plans and future operating results. In addition, the Company may face risks and uncertainties related to other factors that are listed in its periodic reports filed under the Securities Exchange Act. Although the Company believes the expectations reflected in its forward-looking statements are based upon reasonable assumptions, because the statements are subject to risks and uncertainties, the Company can give no assurance that its expectations will be attained or that actual developments and results will not materially differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on the statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

(RURL/G)

RIVERSIDE, CA–(Marketwire – July 12, 2010) – ONRAD Inc., a leader in radiology solutions, including teleradiology, on-site coverage, and technology services, is proud to announce the launch of their new website, which makes it easier for users to navigate and find information on all the company’s radiology solutions. “The new site is a better reflection of ONRAD and provides all the important information about our service offerings,” said Ryan Pahler, Director of Sales and Marketing. The site includes full information on ONRAD’s newest service offerings including on-site radiology coverage, which is available to new and current customers. Users will also find additional information on new Subspecialty Teleradiology interpretation services for Orthopedic and Neurology groups on top of the teleradiology services that they already provide. 

The ONRAD blog (onradinc.wordpress.com) and Twitter (twitter.com/onradnews) pages are also live. “Our goal for the social media pages is to create a space where industry leaders can share information and ideas,” says Pahler, “they’re not intended to be another billboard for our advertising messages, but a place where we can build a community to support others in the industry.” 

“2010 has been a record year so far for ONRAD,” said Brian Phelan, ONRAD’s President and COO. “The foundation of our success has been our ability to address the needs of the radiology community through our flexibility and customizable service offerings,” said Phelan in reference of the company’s recent headlines including the acquisition of a subspecialty radiology provider, and introduction of additional service offerings that include billing operations and on-site staffing solutions. “ONRAD began as a traditional teleradiology provider, but has evolved into a true radiology solutions company.”

As a partner, ONRAD provides more than just teleradiology interpretations. The executive team develops strategies to help customers be more competitive in their local communities. ONRAD’s unique solutions are customized for each customer to help increase profitability and improve patient care.

For more information on ONRAD Inc. visit www.onradinc.com

To read more on this topic, visit: http://www.onradinc.com/?page_id=1818

About ONRAD Inc:

ONRAD is a full service physician-owned radiology provider offering customized radiology services including professional staffing, teleradiology solutions, and technology services. As a partner, ONRAD helps customers become more competitive in their local markets by complementing and expanding the radiology services already in place or providing a comprehensive solution. 

Click here to see all recent news from this company

OXFORD, UK–(Marketwire – July 12, 2010) –  Mirada Medical Limited (“Mirada” or “the Company”)

Oxford, UK and Ohio, US, 12 July 2010: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that Karsten Damgaard-Iversen has joined the Board of the Company as Non-Executive Chairman. 

Karsten Damgaard-Iversen is an internationally accomplished business professional with more than 30 years global experience of working within the healthcare imaging industry. He is a proven leader with a successful track record in operational and strategic management positions within small, medium and large medical imaging and healthcare technology companies. Mr. Damgaard-Iversen, aged 54, combines strong business acumen with in-depth technical and medical knowledge and has served in executive positions such as Managing Director and Chief Group Executive of Toshiba Medical Systems Europe BV, Managing Director of Toshiba Medical Systems (UK) Ltd., Vice President of International Operations of Fisher Imaging Corporation and Director of Sales & Marketing of Storz Medical AG. Mr. Damgaard-Iversen has also been a direct contributor to the invention and development of specific laser and x-ray based medical products. He holds an MBA from Emory University and a BSc in electronic engineering from Copenhagen University College.

In addition to his role as Chairman at Mirada Medical, Mr. Damgaard-Iversen is the founder and director of Disease Control Innovations Medical BV, a Dutch company engaged in product and EU business development of new medical technology that encompass innovative solutions to disease management and diagnosis. DCI Medical currently supports SonoCine Corporation, a privately held US inventor of automated whole breast ultrasound (AWBU) for screen detection of mammograhically occult breast cancer, and US quoted Imaging Diagnostic Systems, a pioneer in laser optical imaging systems.

Commenting on the appointment of the new Chairman, Hugh Bettesworth, CEO of Mirada Medical, said: “I am delighted that Karsten has chosen to join Mirada Medical as Chairman and that we have been able to attract such international talent from the medical imaging industry to our Board. Karsten’s experience in product development, together with his strategic and operational leadership, will provide Mirada with excellent guidance and steering as we continue to grow and prosper in the global oncology imaging marketplace.”

Commenting on his appointment as Chairman of the Board of Mirada Medical, Mr. Damgaard-Iversen said: “I am extremely impressed by Mirada’s innovative solutions for oncology disease management and cross modality decision support systems and I hope to be able to make a significant contribution to the growth and development of the Company. I look forward to working with the team at Mirada and applying my experience and know-how from the medical imaging arena to guide and support the future success of Mirada.” 

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with an enhanced software package for the quantification of images, typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.

NEWPORT BEACH, CA–(Marketwire – July 9, 2010) – Nationwide Health Properties, Inc. (NYSE: NHP) announced today that the Company will release its 2010 second quarter earnings on Monday, August 2, 2010 after the close of trading on the New York Stock Exchange. The Company will host a conference call on Tuesday, August 3, 2010 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) in order to present the Company’s financial performance and operating results for the quarter ended June 30, 2010.

The webcast can be accessed in the Investor Relations section of our website at www.nhp-reit.com. Participants may also join via teleconference by dialing (800) 573-4752 and referencing conference ID number 96821760. The international dial-in number is (617) 224-4324. The earnings release and any additional financial information that may be discussed on the webcast/conference call will also be available on our website. A digitized replay of the conference call will be available from 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) that day until 9:00 p.m. Pacific Time (Midnight Eastern Time), September 3, 2010. Callers can access the replay by dialing (888) 286-8010 or (617) 801-6888 and entering conference ID number 78550756. Webcast replays will also be available on our website for at least 12 months following the conference call.

Nationwide Health Properties, Inc. is a real estate investment trust (REIT) that invests primarily in healthcare real estate in the United States. As of March 31, 2010, the Company’s portfolio of properties, including mortgage loans and properties owned by unconsolidated joint ventures, totaled 606 properties among the following segments: 279 senior housing facilities, 197 skilled nursing facilities, 112 medical office buildings, 11 continuing care retirement communities and 7 specialty hospitals. For more information on Nationwide Health Properties, Inc., visit our website at http://www.nhp-reit.com.

LONG ISLAND, NY–(Marketwire – July 9, 2010) –  SciMeDent Health Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces plans to appoint Dr. Bahige Baroudy of Genesis Biopharma to the equivalent role of Chief Science Officer at TRDX for the continued development of a potential cure for diabetic neuropathy.

Dr. Bahige Baroudy has multi-disciplinary expertise in basic research, infectious disease drug discovery and virology. Prior to joining Genesis Biopharma, Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and earned a place on “The Scientific American 50” list as the top Research Leader in 2003 in this category. He was also the Director, Division of Molecular Virology at the James N. Gamble Institute of Medical Research, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. Dr. Baroudy has also worked at the NIH in several disciplines.

Dr. Baroudy stated: “We are pleased that we have received the approval of Health Canada to proceed to Phase 1 clinical studies.”

Dr. Jan Stahl, CEO of TRDX, commented: “We look forward to the work Dr. Baroudy will execute in bringing this potential cure to market.”

About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

MUNDELEIN, IL–(Marketwire – July 9, 2010) –  Looking to support guidelines from APIC, SHEA, CDC and the Joint Commission for preventing catheter-associated urinary tract infections (CAUTI), Medline Industries, Inc. will be showcasing its evidence-based ERASE CAUTI program and urological products at the upcoming Association for Professionals in Infection Control and Epidemiology (APIC) Annual Scientific Meeting in New Orleans, LA, July 12. 

CAUTI is one of the most common healthcare-associated infections, not only comprising 40 percent of all institutionally acquired infections, but also eight percent of infections in the home care setting. Studies show that one in four patients receives an indwelling urinary catheter at some point during their hospital stay and up to 50 percent of these catheters are placed unnecessarily.

During the three-day exhibition, Medline will demonstrate its ERASE CAUTI program, a revolutionary new approach to managing catheters and reducing CAUTI. Based on the same criteria the CDC used in developing their new CAUTI prevention guidelines, the ground-breaking ERASE CAUTI program features a reengineered one-layered catheter tray coupled with an evidence-based clinical education program.

The Medline clinical team will also be conducting a series of live, multimedia overviews of its cutting edge competency validation tools for assessing and sustaining staff results. The interactive competency programs are available to staff anytime via Medline University, Medline’s online education resource, and can be easily incorporated into the annual skills competency program for a facility’s nursing staff.

Among the additional CAUTI prevention products available in the booth (#1907) for demonstration during the show are exam gloves and hand hygiene compliance tools that support aseptic technique and the BioCon 500 Scanner, which can be used in place of a urinary catheter to assess bladder volumes and reducing the number of catheterizations. Avoiding unnecessary catheter use is a primary strategy for preventing CAUTI.

Additional information on the ERASE CAUTI program is available on Medline’s website at www.medline.com/erase.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

Medline has a growing network of 32 distribution centers around the country, as well as an expanding, dedicated transportation fleet with over 200 vehicles in a variety of sizes to fit customers’ specific delivery needs. The fleet is equipped with the latest navigation devices for enhanced order tracking and communication.

FORT SMITH, AR–(Marketwire – July 9, 2010) –  30 Golden LivingCenters have been selected by the American Health Care Association and the National Center for Assisted Living (AHCA/NCAL) as recipients of the AHCA/NCAL Bronze and Silver Quality Awards this year. To be selected for one of the independently judged awards, nursing homes must show an extraordinary ongoing commitment to quality care for their residents, as measured against specific criteria.

The AHCA/NCAL Quality Awards are designed to recognize quality achievement, while supporting improvement efforts in long-term care through the promotion of education and awareness. The awards are modeled after the Malcolm Baldrige National Quality Award, which is the nation’s highest award for distinguished health care achievement.

Golden Living has earned 267 Quality Awards since AHCA began the program in 1996. In 2010, 20 Golden LivingCenters received a Bronze Quality Award and a record 10 LivingCenters earned the difficult-to-achieve Silver Quality Award.

“More than 70 percent of our current LivingCenters have earned a Quality Award, which is an astounding achievement and a real testament to our company’s quality focus,” said Neil Kurtz, M.D., President and CEO of Golden Living. “This proven record of quality, year after year — truly sets us apart in the industry.”

“Our caregivers are dedicated to providing the highest level of quality care possible to our patients,” said Larry Deans, President of Golden LivingCenters.

To be selected by AHCA/NCAL as a Bronze Quality Award recipient, a nursing home must demonstrate an organization-wide commitment to a patient-centered mission, define its principal customers and their expectations, and indicate how it is striving to meet their needs.

Quality Award recipients at the Silver level must have demonstrated excellence in the core values and concepts of visionary leadership, focus on the future, resident-focused care, management that measures and analyzes performance, organizational and personal learning, valuing staff and partners, systems perspective and innovation, and focus on results and creating value. To be eligible for the more rigorous Silver designation, nursing homes must also have previously earned the AHCA/NCAL Bronze Quality Award.

“We applaud the leadership of Golden Living for demonstrating national distinction in their quest for performance excellence,” said AHCA/NCAL President and CEO, Bruce Yarwood. “Golden Living is at the forefront of the quality movement and we applaud them for their efforts to incorporate processes that demonstrate enhanced quality

A ceremony honoring the recipients of this year’s awards will be held at the AHCA/NCAL Annual Convention and Exposition, Oct. 10-13, 2010 in Long Beach, California.

About Golden Living (www.goldenliving.com)
Golden Living is one of the largest providers of healthcare services in the United States. Golden Living companies operate skilled nursing and assisted living facilities, and provide rehabilitation therapy, hospice care, home health services and healthcare staffing services. The Golden Living family of companies include Golden LivingCenters, Aegis Therapies, AseraCare Hospice and Home Health, and 360 Healthcare Staffing. There are more than 300 Golden LivingCenters in 21 states. Golden Living also offers assisted living services at more than 40 locations. In addition, the Golden Innovations companies partner with more than 1,000 nursing homes, hospitals and other health care organizations in 37 states and the District of Columbia. Collectively, the Golden Living family of companies has more than 40,000 employees who provide quality healthcare to more than 60,000 patients every day.

Golden Living 2009 Quality Award Recipients

Click here to see all recent news from this company

PHOENIX, AZ–(Marketwire – July 8, 2010) –  Brenda J. Fox, MS, ATR-BC, a therapist from the Gatehouse Academy, recently presented a 2.5 hour session in Phoenix, Arizona to introduce how the use of art and art therapy enhances the power of play in play therapy. The participants learned how different art materials are used and can be incorporated into the play therapy session. Each member was also able to participate in an experiential art therapy technique, which can be used with any age group.

The workshop accomplished the following five objectives for the play therapists in attendance:

1. Learn how the use of art therapy enriches and supports play therapy.
2. Understand the benefits of art therapy and play.
3. Discover how various art mediums work in the play therapy session.
4. Learn when to use art material as a therapeutic intervention in play therapy.
5. Learn how to explore anger through experiencing a “hands on” art therapy technique to be used in play therapy.

“We are very proud of the work Brenda has been able to accomplish here at Gatehouse Academy and outside of our drug rehab program,” states Mike Baldassare, Director of Admissions. “She is an integral part of our addiction treatment team and has helped countless residents here get well through the power of Art Therapy.” Brenda currently works with young adults recovering from substance abuse at the Gatehouse Academy in Arizona. Fox has also worked with women with eating disorders and has facilitated family art therapy groups at in-patient settings. Her experience includes speaking at conferences and workshops, teaching didactics, group facilitation, individual therapy, leading retreats, and writing articles on art therapy featured in the Arizona Republic and Seventeen Magazine.

For more information, visit www.gatehouseacademy.com.

About Gatehouse Academy

Gatehouse Academy is a co-educational long term drug rehab program and addiction treatment center exclusively for young adults ages 17 to 25 with chemical dependency and dual diagnosis disorders. Residents are taught responsibility, accountability, life skills, social skills, and work ethic, while receiving an equal blend of therapeutic and clinical services. Twelve-step recovery is the foundation of the program and daily meetings are attended in the community.

NEW YORK, NY–(Marketwire – July 8, 2010) –  MedLink (OTCBB: MLKNA), a leading provider of Electronic Health Records and practice management solutions, is pleased to announce the acquisition of LabTestPortal, a direct-to-consumer laboratory testing platform. The acquisition provides MedLink with an entry into the direct-to-consumer laboratory testing market which has gained significant traction in the more than $50 billion U.S. laboratory testing market. 

LabTestPortal is a service provider that delivers direct-to-consumer secure and confidential laboratory testing to consumers, that eliminates the need to see a primary care physician and receive insurance approval for maintenance and advanced lab tests. Through a Personal Health Record portal, consumers are able to track their lab testing results as well as store vital healthcare documents and information and receive results in most cases in less than 48 hours.

Ray Vuono, President of MedLink, stated, “The market for DTC lab testing has experienced an annual growth rate of 15-20 %, due to Consumers continuing to take charge of their own health through disease prevention and early detection. With managed care companies, as well as Medicare and Medicaid refusing to pay in most cases for tests without ‘symptoms of disease,’ DTC laboratory testing presents the only avenue for disease prevention for most consumers.” Mr. Vuono continued, “MedLink’s entry into the DTC lab test market, establishes a differentiator for MedLink in the EHR and Healthcare IT marketplace, providing services and synergies that enhance MedLink’s overall offering not only to the end user patient but as an added benefit to the MedLink Lab outreach program and RHIO Financial Sustainability model.”

About LabTestPortal.com

LabTestPortal.com (LTP) is a service provider that delivers direct-to-consumer secure and confidential laboratory testing, alleviating the need to spend precious time waiting to see a primary care physician for consumers. LTP provides a Personal Health Record portal where consumers are able to track their lab testing results as well as store vital healthcare documents and information. LTP is a necessary tool for all consumers to better manage their health through monitoring and education. The Personal HealthCare revolution is in its early stages and LTP is a bold and fresh part of this new and innovative methodology of personal healthcare. We are dedicated in providing the most comprehensive customer service with an affordable and secure product offering available to consumers in all 50 states.

About MedLink

MedLink is a healthcare IT company that provides the medical community with products and services designed to help create, manage, and share medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-K available through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

MUNDELEIN, IL–(Marketwire – July 8, 2010) –  Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost management prime vendor agreement for distribution services with Southeast Supply Solutions, LLC (SESS) based in Tampa, Fla. The five-year agreement, which began June 1, 2010, is anticipated to save SESS’ member hospitals an estimated $18 million over the term of the contract.

SESS, a limited liability corporation owned by select VHA Southeast members located throughout Florida and Alabama, enables members to align supply chain strategies that leverage aggregated supply volume to drive supply chain cost reductions and improve operating efficiencies.

Medline is expected to generate more than $360 million in medical and surgical distribution sales from the partnership over the term of the agreement.

According to Sidney Hobbs, Medline’s Vice President of National Accounts, “Medline will provide full distribution services to SESS members, which together comprise 18 hospitals. Medline will drive cost savings to SESS through operational efficiencies and cost reductions throughout the distribution channel and from Medline brand product purchases. Medline will distribute products direct to the healthcare facilities from its Orlando distribution center and a new distribution facility in Alabama, expected to open in 2011.”

Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, clinical education and practical solutions to help the facility control costs and improve patient care and safety.

“The commitment by the SESS members to Medline sets the foundation for current and future operation efficiencies resulting in lower supply chain costs,” said James Etherton, Director Materials Management, Bay Medical Center and SESS Operating Committee Chairman.

About Southeast Supply Solutions (SESS)
SESS, a limited liability corporation owned by eight VHA Southeast members, enables members to align supply chain strategies that leverage aggregated supply volume to drive supply chain cost reductions and improve operating efficiencies while maintaining the highest quality of care for the communities. The eight member owners of SESS include: Baptist Health (Montgomery, AL); Baptist Health Care Corporation (Pensacola, Fla); Bay Medical Center (Panama City, Fla); Citrus Memorial Health System (Inverness, Fla); DCH Healthcare Authority (Tuscaloosa, Ala); Lakeland Regional Health Systems, Inc. (Lakeland, Fla); Parrish Medical Center (Titusville, Fla); University Community Hospital, Inc. (Tampa, Fla).

About Medline Industries, Inc.
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and health care systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

PARAMUS, NJ–(Marketwire – July 8, 2010) –  Advanced Data Systems (ADS) has become the first New Jersey-based, practice management / EMR provider of healthcare information exchange solutions by RelayHealth. This partnership brings the patient-centric connectivity solutions of RelayHealth into the physician office for enhanced patient communication and improved efficiency.

RelayHealth connects members of the Jersey Health Connect health information exchange (HIE) in New Jersey. ADS will now offer RelayHealth patient engagement tools to physicians throughout the state and beyond. The affiliation with RelayHealth will result in unparalleled connectivity for ADS’ clients among and between each other. This connectivity will also position providers well for inclusion in Jersey Health Connect and other health information exchanges. 

David Barzillai, President of ADS said, “RelayHealth’s healthcare information exchange tools give physicians a monumental step toward interconnectivity between patients, providers and resources. ADS, as a New Jersey-based company and leading provider of healthcare automation solutions to thousands of providers, is extremely proud to be the first such company to work with RelayHealth in this initiative, and to work for the expanded exchange of health information in New Jersey and beyond.”

Mike Lang, Senior Vice President, Sales, for RelayHealth said, “ADS has a longstanding and notable history in New Jersey. We’re pleased that ADS will expand the availability of patient-centric health information exchange tools in this key market. We look forward to working with ADS, and in bringing RelayHealth’s dynamic connectivity capabilities to clients of ADS throughout the state.”

The Federal government has awarded ARRA funds to HIEs across the nation, including in New Jersey. The objectives of the awards include facilitating information exchange to improve healthcare delivery services, to coordinate patient care while maximizing efficiency and reducing redundancy, and to provide patients safe and secure access to their health information. 

More information on ADS can be seen by visiting www.adsc.com. 

About Advanced Data Systems: ADS (www.adsc.com) is a leading provider of healthcare automation solutions to (1) medical practices of every size and specialty, (2) radiology and imaging centers, and (3) revenue cycle management companies. ADS produces its own systems which include the MedicsDocAssistant, 4.0.1 CCHIT Certified® 2008 Ambulatory EHR, MedicsPremier and MedicsElite for comprehensive Practice Management, and the MedicsRIS/PACS for Radiology. ADS provides quick Implementation, comprehensive Training and excellent ongoing Support which always includes updates. The company performs data conversions from existing systems and interfaces to existing systems. ADS’ solutions can be configured as Client Server or ASP, and all of the company’s systems (EHR, PM, RIS and PACS) are available separately per the needs of the practice. Over 35,000 physicians rely on solutions from ADS.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – July 8, 2010) – DiaMedica Inc., (TSX VENTURE:DMA) today announces that it has initiated a Type 1 diabetes program. The recently announced Sanomune acquisition allows DiaMedica to expand into Type 1 diabetes. The initiation of this program is based on encouraging preclinical results with DM-99, a naturally occurring protein that the company has previously shown to have clinical efficacy for Type 2 diabetes.

In the study, animals were injected with streptozotocin, a naturally occurring compound known to be toxic to beta cells, to mimic the disease. A week after this streptozotocin treatment, animals were injected twice daily with DM-99 for a period of 21 days at which time fasting blood glucose measurements were taken. Animals treated with DM-99 had a statistically significant 68% (p=0.05) reduction in fasting blood glucose compared to untreated animals. Furthermore, the DM-99 treatment resulted in a positive reduction in total glucose as measured by an oral glucose tolerance test.

“Initial results from this study show that DM-99 was able to reduce fasting blood glucose, an indication that new beta cells may be created or that existing beta cells are being protected from the streptozotocin insult,” stated Rick Pauls, President and CEO of DiaMedica. “The final results and analysis of DM-99 on the direct effects upon the pancreas (insulin production and beta cell proliferation) is expected during the summer of 2010.”

About Type 1 Diabetes

According to the Juvenile Diabetes Research Foundation, as many as 3 million Americans may have Type 1diabetes, an autoimmune disease that strikes children and adults suddenly and can be fatal. In Type 1 diabetes, the host’s own immune system destroys beta cells in the pancreas that normally control blood sugar level by producing insulin. Currently, patients with Type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times each day, or use a pump daily to control blood sugar levels. Even with intensive care, insulin is not a cure for diabetes, nor does it completely prevent the eventual and devastating complications of diabetes, which may include kidney failure, blindness, heart disease, stroke, and amputation.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s Type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with Type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions.These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

NEW YORK, NY–(Marketwire – July 8, 2010) – SREH Scientific News International (PINKSHEETS: SREH) (www.scientificnewsroom.com) announces today confirmation to attend the American Academy of Family Physicians (AAFP) Scientific Assembly to be held at the Colorado Convention Center in Denver, Colorado September 29^th – October 2^nd, 2010. The conference, held annually, is the premier event for AAFP members covering Clinical topics, Population-based care, Patient-based care and Clinical Procedure Topics with a multitude of sub-categories therein to suit medical professionals from around the country.

The American Academy of Family Physicians is one of the largest national medical organizations, representing more than 94,700 family physicians, family medicine residents and medical students nationwide. Founded in 1947, its mission has been to preserve and promote the science and art of Family Medicine and to ensure high-quality, cost-effective health care for patients of all ages. The Mission of the AAFP is to improve the health of patients, families and communities by serving the needs of members with professionalism and creativity. Initiatives include advocacy, practice enhancement, education and health of the public.

SREH CEO Tony Dibiase believes, “This will be an excellent way to kick-off the Fall Conference season for SNI’s exclusive coverage on the medical industry. Our medical writers have pre-approved press credentials and will be in attendance to feature the meeting highlights for our trademarked publication, The Podium Report. Over 90,000 AAFP members will receive the preliminary news report via email and be able to access the complete meeting highlights on www.scientificnewsroom.com on demand. This is beneficial to both those that are not able to attend and for those that did attend and would like a re-cap. Either way, the information becomes exponentially productive when implemented with our soon to be released Doctor2Doctor social networking platform.”

This year’s Assembly includes new features such as The Learning Gallery, with presentations on important, medically relevant issues; exhibitor’s products, products in clinical development, disease state data, and physician-sponsored evidence-based studies. It also will feature an unparalleled opportunity for exhibitors to showcase the latest in technology, products, equipment, and services related to the specialty of family medicine.

“This is the first of many events on our calendar for the year in building the information database and accessible archives for medical professionals everywhere,” states Dibiase. “With more information comes increase in industry position and overall profitability with the ability to further cross-implement the cutting-edge features of SNI such as the iPhone/iPad news feed application and SNI’s one-of-a-kind social networking matrix, Doctor2Doctor, among others. As always, we continue to be the only independent medical news company in the world that manages to deliver both quality and quantity with integrity as a subscription-based provider with no influence from sponsors. We expect to see our paid member base increase significantly over the next few months as we continue to announce company developments, meeting attendance, and key strategic relationships.”

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premier all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription-based without bias from any medical or pharmaceutical provider. 

In the beginning, there was… Fishing, Manga, global tide reports and more! Get your iPhone Mobile2Earth (www.mobile2earth.com) app now. Choose from the iPhone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more! Get ready, as Mobile2Earth unleashes phase 1 of its iPhone app releases for mass consumption. 

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

CLARKSVILLE, TN–(Marketwire – July 8, 2010) –  Premier BPO, Inc. today has announced that they have entered into an agreement with JT Healthcare Services, LLC for the purposes of establishing a Chinese based Joint Venture to provide back office billing and data management services. This Joint Venture is expected to support JT Healthcare Services, LLC’s planned revenue cycle management business in service to U.S. Hospitals.

Premier BPO, Inc. is a leading provider of BPO and KPO services to North American and European Companies. From its headquarters in Clarksville, Tennessee, Premier BPO delivers its services to the world’s best companies from multiple geographies including China, The Philippines and Pakistan. Premier lowers the cost and improves the quality of a client’s back office operations. Premier was founded in 2003 by an industry savvy team of Senior executives, with over 125 years direct combined experience in the outsourcing and off shoring industry who have implemented hundreds of programs, covering thousands of highly educated, deeply skilled agents, in multiple countries across the globe.

Premier has created a strategic relationship with the Chinese government to provide training and facility cost deferrals, building a “center of excellence” specifically dedicated to Medical Billing in Kunshan, China, approximately 45 kilometers from Shanghai, and has access to an extremely large, highly educated work force in the Jiangsu Province which has 115 Colleges and Universities supplying hundreds of thousands of English literate graduates.

JT Healthcare Services, LLC is positioned to be a leading provider of full revenue cycle outsourcing (RCO) services to healthcare providers through aggressive organic and acquisitive growth. Their founding management team consists of seasoned executives that pioneered the industry and built successful RCO businesses with integrated technology offerings. Through this joint venture with Premier BPO, JT Healthcare will leverage a BPO model using scale and automation to elevate service levels while lowering costs and increasing profit margins for hospitals and physician groups in this $50B revenue cycle processing market with huge untapped scale opportunities. Most revenue cycle processing is still performed in-house at hospitals with inefficient and sub-scale back-office operations suffering from economic and governmental pressure to reduce costs and focus on clinical operations.

The partnership created by Premier and JT Healthcare Services will provide end-to-end RCO services which will provide the perfect solution for this crippling drain on health care providers.

Click here to see all recent news from this company

LONDON–(Marketwire – July 8, 2010) –   Frederic H. Moll, M.D., co-founder and executive chairman of the board of directors for Hansen Medical, Inc., will present at the Royal Society of Medicine’s (RSM) annual Medical Innovations Summit on July 11, 2010.

What: Dr. Moll will highlight the success and benefits of the company’s Sensei® X Robotic Catheter System and its Artisan™ Extend Control Catheter. The Sensei X Robotic Catheter System allows physicians to instinctively position robotic catheters in difficult anatomical locations within the heart in a stable and controlled manner. The system consists of a physician workstation capable of controlling a robotic arm, which is attached near the foot of the procedure table. The robotic arm maneuvers the Artisan Control Catheter. Studies demonstrate that use of Hansen Medical’s robotic platform help to increase safety and reduce both radiation and fluoroscopy exposure.

When: Sunday, July 11, Session 4, 12:30 – 13:30, followed by a Q&A session with all speakers.

Where: The Royal Society of Medicine, 1 Wimpole Street, London W1G0AE, UK.

About The Medical Innovations Summit 2010: The Royal Society of Medicine has always been the home of medical education and is fast becoming a vital source of information on medical innovation. The RSM is eager to ensure its members and guests are kept updated and informed on the latest developments in medicine and healthcare. This year’s program features guest speakers from around the world with an intensive focus on the latest medical breakthroughs. For additional information, visit http://www.rsm.ac.uk/innovations or contact:

Carmel Turner
Media Manager, RSM
020 7290 2904
07949516471

About Hansen Medical: Hansen Medical, Inc. (NASDAQ: HNSN), based in Mountain View, California, USA, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company’s Sensei® system and its Sensei X Robotic Catheter System are compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the European Union, the Sensei and the Sensei X systems are cleared for use during Electrophysiology (EP) procedures, such as guiding catheters in the treatment of Atrial Fibrillation (AF). The remote navigation platform was cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. The safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF have not been established. Additional information can be found at www.hansenmedical.com.

Hansen Medical, Heart Design, Hansen Medical & Heart Design, and Sensei are registered trademarks, and Artisan is a trademark of Hansen Medical, Inc. in the United States and other countries.

GARRISON, NY–(Marketwire – July 7, 2010) –  Aurora Information Technology (Aurora IT), a medical website design and medical marketing firm, has been hard at work this year launching a number of exciting new websites. “Nowadays, patients consults Internet first for medical information,” explained Daniel Gilbert, CEO of Aurora IT. “As medical and physician website designers, we know that the best websites contain educational and keyword-packed information in order to get found by search engines and prospective patients.” Gilbert and his team at Aurora IT successfully launched the following medical websites:

Health Options Worldwide – HOW – www.healthoptionsworldwide.com: HOW is an interactive medical tourism website that allows users to search for medical providers that offer low rates for treatments, domestically and internationally.

Dr. Ridwan – www.drridwan.com: Renowned NY urologist Dr. Ridwan Shabsigh’s new website features a new logo and a web-based men’s health program, “The Dr. Ridwan Show,” which covers common topics in men’s health.

Rockland Eye Physicians & Surgeons – www.rocklandeye.com: The new website for Rockland Eye, providers of general ophthalmology for children and adults, features patient education videos, doctor biographies, insurance information and a user-friendly contact form.

Autosafe Medical – www.autosafemedical.com: Medical device company AutoSafe Medical’s website redesign showcases their flagship product, AutoSafe Advantage™, a single safety solution that fits any needle or syringe configuration, with an auto launch product page video.

Urgent Care MDs – www.urgentcaremds.com: UrgentCareMDs’ full service, extended hours urgent care got a new website and branding that demonstrates their commitment to evidence-based quality health care.

LA Ortho Experts – www.laorthoexperts.com: LA Ortho Experts’ newly redesigned website incorporates brilliant photography and detailed conditions and treatments for the back, spine, neck, knee and shoulder. The site also has a convenient “free MRI review” form, Hot Topics and patient educational videos.

N.Y. Neurological Associates – www.nynapc.com:
The new website for this general neurology and physical therapy practice offers information common neurological conditions and treatments, physician biographies and resources such as links, affiliated hospitals, insurance information and forms.

Sockolov & Sockolov – www.sockolov.com:
Sockolov & Sockolov based in Sacramento, California, provides top-notch medical care to their community and continuous medical training to practitioners. Their Medical Research facility conducts ongoing investigational studies to address the most common and critical health challenges.

Click here to see all recent news from this company

WAYNE, PA–(Marketwire – July 7, 2010) –  Clinical and Laboratory Standards Institute (CLSI) will showcase StatisPro™, its new method evaluation software, at the AACC/ASCLS Annual Meetings and Clinical Lab Expo in Anaheim, California, from July 27 through July 29. StatisPro will make it easier for laboratory professionals to perform the statistical analysis necessary to implement recognized CLSI guidelines when evaluating a clinical method. StatisPro can be used to demonstrate that clinical methods conform to accreditation or regulatory requirements.

Developed in conjunction with Analyse-it®, StatisPro method evaluation software is easy to use, provides clear step-by-step advice on performing a study, and is the only software to faithfully implement the eight most popular CLSI method evaluation guidelines. StatisPro will be demonstrated by experts at CLSI booth #6623 during the Clinical Lab Expo.

The CLSI President’s Message session on July 26 at 10:30 AM, in the Anaheim Marriott Hotel Platinum Ballroom 7, will feature a presentation on StatisPro. Participants will have the opportunity to hear an initial perspective on the StatisPro software capabilities. The event will also include information about new strategies for point-of-care testing devices and innovations for newborn screening by tandem mass spectrometry.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information on CLSI, visit the CLSI website at www.clsi.org or call 610.688.0100.

Analyse-it Software, Ltd. formed in 1997 to develop statistical analysis and charting software for Microsoft® Excel™, and built its flagship product, Analyse-it, through work with some of the world’s largest in vitro diagnostic companies. Now with more than 20,000 customers, Analyse-it is highly respected in the scientific and research community, and is used and cited in thousands of peer-reviewed published papers. For additional information, visit the Analyse-it website at www.analyse-it.com.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 7, 2010) –  At the recent 25th Annual European Association of Urology Congress, Dr. David Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City, presented findings that showed that obesity does not adversely impact the outcomes of robotic-assisted laparoscopic prostatectomies (RALP) for prostate cancer treatment. These findings contradict the popular opinion that non-obese patients fare better than their obese counterparts after having robotic surgery for prostate cancer.

Dr. Samadi presented findings from a study that followed 1,112 men who underwent RALP for prostate cancer treatment. The results were that the perioperative, pathologic, and functional outcomes were the same regardless if the patients were obese or not. “Previously it had been thought that obese patients do not do well after RALP because of the way their high BMI affects their outcomes, but there wasn’t enough data to support that notion,” said Dr. Samadi. Ironically, previous data has shown that obese patients have worse outcomes with traditional open prostatectomy versus a robotic prostatectomy.

In fact, the new study showed that both obese and non-obese subjects had similar Gleason scores (a grading system used to predict the behavior of prostate cancer), positive margins, biochemical recurrence, and surgical complications. They had comparable operating times and approximate blood loss. Their post-operative continence rates were similar at three, six, and 12 months. Their post-operative sexual function rates were also very similar at the same stages. “While there is an increased incidence of prostate cancer in men with high BMI, the bottom line is that RALP is effective and safe for these types of patients,” Dr. Samadi said.

“The only barrier to operating on an obese patient would be the surgical challenges that arise as a result of their body mass,” explained Dr. Samadi. A typical RALP takes Dr. Samadi about 90 minutes to perform. With obese patients, surgeries can often go beyond three hours, and if the surgeon does not have the required experience with these kinds of cases, many complications such as DVT, blood clots in lower extremities or overall edema can arise. “I always recommend that a very experienced, high-volume surgeon perform the procedure,” advised Samadi.

Click here to see all recent news from this company

COLCHESTER, VT–(Marketwire – July 7, 2010) –  Competitive Computing, Inc., also known as C2, announced today that they have been selected as a preferred technology services partner by Vermont Information Technology Leaders, Inc. (VITL). VITL is a not-for-profit organization that assists Vermont physician practices and hospitals with implementation of Electronic Health Records (EHR) systems and achieving meaningful use of those systems.

“We are excited to be selected as a preferred technology services provider in partnership with VITL,” said Martin Thieret, Founding Partner, Enterprise Infrastructure Solutions. “We look forward to working with physician offices throughout Vermont to provide cost effective and secure information technologies for electronic health records and practice management systems.”

To facilitate a rapid and successful EHR implementation, C2 offers a set of standard services and preferred pricing for physician practices that include:

• EHR Technical Assessment and Recommendations
• Design, Implementation and Training
• Proactive, Ongoing Management, Security and Systems Monitoring

“VITL’s goal is to provide physician practices with carefully-selected preferred partners that they can feel confident doing business with,” said David Cochran, MD, President and CEO of VITL. “We are pleased that C2 has met our criteria and has been added to our growing list of partners,” continued Cochran.

About VITL
VITL is a non-profit organization with a mission of collaborating with all stakeholders to expand the use of secure health information technology to improve the quality and efficiency of Vermont’s health care system. www.vitl.net. 

About C2
Competitive Computing (C2) is a leading Vermont IT solutions firm that helps organizations achieve competitive advantage by leveraging advancing technology solutions. They offer a comprehensive set of IT services that includes design, implementation, protection and management of IT environments for EHR and practice management needs. C2 also provides a complementary suite of service offerings that includes Physician Practice and EHR Management, Mission-Critical Support Services, Unified Communications, Enterprise Infrastructure Services, Multi-Channel eCommerce and eGovernment Services. C2 is a women-owned, small business celebrating its 17th year in business in 2010. www.competitive.com.

Click here to see all recent news from this company

SAN JUAN, PR–(Marketwire – July 7, 2010) –  After a lull brought on by the global recession, Puerto Rico appears to be bouncing back as one of the world’s top destinations for life science companies. Two U.S. companies — Blu Pharmaceuticals and a DuPont business, Pioneer Hi-Bred — announced new manufacturing and R&D facilities on the island during the past several months.

With Amgen, Eli Lilly and Abbott Laboratories investing $4 billion in the island over the past seven years, Puerto Rico rapidly became the world’s third largest biotech manufacturer, earning it the nickname “Bio Island.” Puerto Rico also has one of the largest concentrations of pharmaceutical manufacturing operations in the world and produces 13 of the top 20 blockbuster drugs sold in the United States.

Most recently, Pioneer Hi-Bred announced a new state-of-the-art research and development facility in Salinas on the southern coast of Puerto Rico to complement its existing trial seed production facility. The $6 million facility is expected to employ 100 scientists, agronomists and others.

“Puerto Rico was a smart choice for many reasons,” said John Soper, Pioneer Vice President of Crop Genetics Research and Development. He noted that the island has the same regulatory framework as the mainland United States, a longer growing season suitable for planting crops year-round and a steady stream of quality talent coming out of the University of Puerto Rico.

Pioneer also worked closely with the Puerto Rico Industrial Development Company (PRIDCO), a governmental economic development agency, to take advantage of aggressive new economic incentives.

“The new Pioneer laboratory is exactly the kind of investment the Government of Puerto Rico has been working to foster to help move our island into R&D and other aspects of an innovation economy,” said PRIDCO’s Executive Director Javier Vázquez Morales.

Kentucky-based Blu Pharmaceuticals also opened a new generic drug manufacturing facility in Dorado in March. The company is expected to invest $60 million in the facility during the next three years and employ nearly 250 people as it manufactures seven different medicines it will supply to the U.S. government.

“The stars aligned for us in Puerto Rico,” said Bill Luster, President of Blu Pharmaceuticals. “We were able to acquire a state-of-the-art manufacturing facility for pennies on the dollar of what it would have cost for us to build an operation from the ground-up, plus we were able to tap into a highly talented workforce.”

For more information, visit www.pridco.com.

For free broadcast quality downloads of b-roll and other videos and additional press materials, visit newsinfusion.com.

id=”nav_links”>

SAN MATEO, CA–(Marketwire – July 7, 2010) –  AtHoc, Inc., the pioneer and leader in network-centric emergency mass notification systems, today announced that the United States Army Garrison Walter Reed and Walter Reed Army Medical Center (WRAMC) will deploy its award-winning AtHoc IWSAlerts™ system to help alert personnel in the event of an emergency and to rapidly communicate mission-critical information. The planned implementation of AtHoc’s technology will support as many as 10,000 military and civilian personnel at WRAMC, Walter Reed Army Institute of Research and the Armed Forces Institute of Pathology. 

The AtHoc network-centric mass notification system will be deployed onsite behind Walter Reed’s NIPRNet firewall and will run using Microsoft-based servers and databases. The AtHoc solution will use the garrison’s existing IP network services and will leverage a centralized, Web-based architecture to deliver reliable and secure emergency notifications to all personnel. The system is fully compliant with the Department of Defense’s (DoD’s) Unified Facilities Criteria and the National Fire Protection Association Alarm and Signaling Code (NFPA 72) for net-centric emergency mass notification.

The AtHoc system will deliver alerts through the telephone, with text messaging, and with intrusive audio/visual pop-up alerts to personnel connected to the IP network via desktop, laptop and any other networked device. Alert responses from recipients will be captured and reported to emergency managers in real time to provide an enterprise personnel accountability picture of the safety and status of all personnel. 

In addition to mass emergency alerting, the AtHoc system can be used for healthcare-specific scenarios such as a personnel recall in the event of mass casualty incident, or to quickly disseminate accurate information when dealing with a disease outbreak. 

AtHoc is the No. 1 provider of network-centric mass notification systems to the U.S. military and is currently deployed at 185 installations, protecting more than 1.3 million personnel worldwide. AtHoc specializes in enterprise deployments supporting entire geographically dispersed organizations — major commands, regions and services — from a private cloud application, hosted at internal DoD data centers. This new agreement is the latest in a series of significant DoD medical deployments by AtHoc. Recent deals include the U.S. Army Irwin Health Care Clinic at Fort Riley and Lyster Army Medical Clinic at Fort Rucker.

“The agreement with Walter Reed continues the successful rapid adoption of AtHoc IWSAlerts by the U.S. Army to support their command (IMCOM) emergency mass notification initiatives,” stated (Ret.) Army Col. David Brown, director of Army operations for AtHoc. “The scale of this deployment is significant as it clearly demonstrates the enterprise-class capabilities of the AtHoc platform and its ability and flexibility to address the unique requirements of an Army garrison and an Army medical center.”

AtHoc’s innovative solution represents the evolution of mass notification technology to a third generation able to leverage existing IP networks to (a) communicate emergency information rapidly to all connected devices; (b) integrate and unify disparate existing mass notification capabilities; (c) provide bi-directional communication allowing collection of feedback from all personnel; and (d) achieve enterprise-level scalability and processes. The result is the most effective enterprise-wide mass notification capability with the best cost-to-benefit ratio. 

About AtHoc
AtHoc is the pioneer and recognized leader in providing network-centric emergency mass notification systems to military, homeland security, government and commercial organizations. AtHoc’s products are used for physical security, force protection, personnel accountability, recall and regulatory compliance. Millions of end-users worldwide, in organizations such as the U.S. Air Force, U.S. Army, U.S. Navy, U.S. Coast Guard, NASA, UCLA, Microsoft, Boeing and Raytheon rely on AtHoc’s unified notification systems for their emergency alerting and critical communication needs. AtHoc has partnered with market leaders including Microsoft, Cisco, Dell, Harris, Siemens, Northrop Grumman, MIR3, Lockheed Martin and others to bring these notification solutions to the public and commercial markets.

For more information on AtHoc, please visit http://www.athoc.com.

ENGLEWOOD, CO–(Marketwire – July 7, 2010) –  BioMedical Technology Solutions Holdings, Inc. (OTCBB: BMTL) (“BMTS”) is pleased to announce that it is placing an additional Demolizer® II System in American Samoa representing its third placement in the past 30 days within the V.A. Health Network. The Demolizer® II provides a simple, safe and environmentally friendly means to manage medical waste generated in support of the care of U.S. veterans.

“With 153 large medical centers and over 700 outpatient centers, the V.A. represents an excellent opportunity for our company,” says Don Cox, BMTS’ President and C.E.O. “The placement of the third system in a short period of time represents a natural progression within the V.A. Health Network. This also further validates our plans to expand into the government and military markets.”

The Demolizer® II delivers long term cost advantages compared to traditional hauling options and improved personnel safety and facility security since hauling trucks no longer need to enter V.A. facilities. For these reasons, BMTS expects to expand product placement at V.A. facilities and outpatient clinics over the coming months.

About BioMedical Technology Solutions Holdings, Inc.

BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS’ patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS’ products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. For more information, visit www.bmtscorp.com or call 866-525-2687.

About the Demolizer® II

The Demolizer® II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 47 states after review by 78 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal.

Safe Harbor for Forward Looking Statements

The statements contained in this press release may include certain projections and forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve a number of risks and uncertainties. Such statements reflect the Company’s current views with respect to future events and financial performance. No assurances can be given however, that these events will occur or that such expectations will be achieved and that actual results could differ materially from those described. Actual results of future operations of BioMedical Technology Solutions Holdings, Inc. may differ materially from those indicated by these forward looking statements as a result of various important factors.

ROCHESTER, MI–(Marketwire – July 7, 2010) –  OPTIMIZERx Corporation (OTCBB: OPRX) announced today that it has signed an agreement with Carilion Clinic to implement its SampleMD™ solution to allow its doctors and staff a more efficient way to search, select and distribute sample vouchers, prescription co-pay coupons and other support information right from their desktops.

Carilion Clinic is a healthcare organization with more than 600 physicians in a multi-specialty group practice and eight not-for-profit hospitals that specializes in patient-centered care, medical education and clinical research, with a goal of providing the best possible health outcome and healthcare experience for each patient. 

“Our providers are very sensitive to the costs involved when prescribing brand name medications. The SampleMD platform allows our practitioners a better way to provide sample vouchers to make sure they can tolerate any new medications prescribed or co-pay coupons to help them continue to stay on their medication,” said Howard B. Graman, MD, Carilion Clinic Chair, Primary Care and Regional Medicine.

“We are excited to launch this important initiative with Carilion Clinic to provide an integrated electronic platform that reduces workflow interruption while providing more support to more patients,” said David Harrell, Chairman and Founder of SampleMD. “It is right in line with the Carilion Clinic’s mission to provide the highest quality health care for the individuals, families, and communities they serve.”

For more information on SampleMD, go to www.samplemd.com.

About OPTIMIZERx Corporation

OPTIMIZERx provides unique platforms to help patients better afford and comply to their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient access and adherence to their products.

About Carilion Clinic

Carilion Clinic is a multi-specialty healthcare organization with more than 600 doctors and eight hospitals, based in Roanoke, Va. Led by physicians, Carilion Clinic is committed to clinical excellence, education and research. Carilion Clinic is dedicated to providing care that is centered on the patient’s needs, supported by an ongoing commitment to quality and service. With nationally recognized specialists, award-winning nurses, the latest technology and state-of-the-art facilities, Carilion Clinic is bringing tomorrow’s healthcare into focus today. For more information, please visit www.CarilionClinic.org.

‘SAFE HARBOR’

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CHICAGO, IL–(Marketwire – July 7, 2010) –  The National Council of State Boards of Nursing (NCSBN^®) Board of Directors approved an overall passing standard of 55, with no individual section of the test at a scoring level below 50, for the Pearson Test of English Academic (PTE Academic). This decision is consistent with the previous passing standards recommended for other English language tests and the level of English proficiency needed to perform entry-level nursing safely and effectively. This recommendation also supports the NCSBN policy position on international nurse immigration, which states that “domestic and international nurses need to be proficient in written and spoken English skills.”

NCSBN has approved similar passing standards on English language proficiency tests for the Test of English as a Foreign Language Computer-based Test (TOEFL CBT) in 2003 and for a version of the TOEFL Internet-based Test (TOEFL iBT^®), as well as for the International English Language Testing System (IELTS^™) examination. NCSBN is now providing its member boards with another option for evaluating English language proficiency of licensure applicants by setting a minimum English proficiency requirement with PTE Academic. Given the number of internationally educated nurses who seek licensure in the U.S., defining a legally defensible passing standard, documenting the procedures used to identify that standard, and making the standard available to boards of nursing and other interested parties is a benefit to member board jurisdictions.

PTE Academic was developed to measure the English communication skills of nonnative English-speaking students in an academic environment. Owned and developed by Pearson, the test was cross-validated in several countries, including the United Kingdom, Australia and the U.S., to ensure that the test is representative of and measures international academic English. PTE Academic measures four English language skills via integrated test items: Writing, Speaking, Reading and Listening. For more information about PTE Academic, visit http://pearsonpte.com/PTEAcademic.

“Setting an English Language Proficiency Passing Standard for Entry-Level Nursing Practice Using the Pearson Test of English Academic,” an NCSBN NCLEX Technical Brief, can be found on the NCSBN website at https://www.ncsbn.org/1233.htm.

The National Council of State Boards of Nursing (NCSBN) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also four associate members.

Mission: The National Council of State Boards of Nursing (NCSBN), composed of Member Boards, provides leadership to advance regulatory excellence for public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  EmpowHER is offering free access to world-class health information as well as a community of experts and advocates to the millions of women interested in current research on cord blood and stem cells. These resources are offered in support of the Cord Blood Awareness Month, which occurs in July and is sponsored by the American Hospital Association.

Cord blood is the blood located inside the umbilical cord after the cord has been cut. It is rich with stem cells, which have the ability to regenerate and form cells that create all other tissues, organs, and systems in the human body. The unique and special characteristics of cord blood cells provide the possibility of healing some cancers or inherited diseases. Also, according to the American Pregnancy Association, cord blood stem cells are oftentimes rejected less by the body as compared to healthy adult bone marrow stem cells. If a parent elects to do so, cord blood can be stored at the time of an infant’s delivery for medical use in the future. Some experts question the effectiveness of storing cord blood, however, as it may contain the same cells that caused a disease or medical condition in the child, the National Institutes of Health reports.

According to research published in the Journal of Reproductive Medicine, 3 out of every 4 pregnant women consider themselves only “minimally informed” about this issue.

For women wanting to learn more about this issue, EmpowHER offers invaluable content on its site where women can find topical medical articles and guides to additional online resources on cord blood and stem cell research and therapies.

To access cord blood content on EmpowHER, please click the links below:
Cord Blood Resource Page
Thinking About Cord Blood Banking?
Cord Blood Donation
Cord Blood Banking – The Medicine of the Future?
Growing New Organs From Cord Blood – Why Transplants May Not Be Needed In Future
Can Obama Cure Cancer With Stem Cell Research?

“More women need to understand what cord blood donation really entails and what the reasons behind it are,” says Michelle King Robson, EmpowHER’s Founder, Chairperson and CEO. “This way, pregnant women considering cord blood donation can make more informed decisions when offered this option at childbirth.”

About EmpowHER
EmpowHER is an award-winning health media company for women. The Company’s website provides visitors access to one of the largest women’s health and wellness content libraries on the web, as well as the largest online community of women discussing their health and wellness issues. EmpowHER promotes a “24 Hour Promise” to its visitors, who can come to the site, ask any health question and receive a response within 24 hours. Health care marketers rely on EmpowHER for reaching the most influential health and wellness buying audience on the Internet — women. Millions of women visit EmpowHER.com every year, making it one of the largest and fastest-growing resources dedicated exclusively to women’s health and wellness. For more, visit www.empowher.com.

Click here to see all recent news from this company

HALLOWELL, ME–(Marketwire – July 6, 2010) – Granite Hill Estates (GHE) has added two more sessions to its Life Enrichment Series, dedicated to personal, intellectual, and spiritual enrichment. The first session — “Wills and Estates” — will be presented on Monday, July 12, 2010 at 6:00 p.m. The second session — “The Role of Physical Therapy in Improving Your Health” — will be conducted on Tuesday, July 13, 2010 at 11:00 a.m. Both sessions will be held in the Media Room at Granite Hill Estates.

“The Life Enrichment Series is a great resource for GHE residents, our families, and others in the greater Hallowell community who are interested in these important topics,” said Bob Bond, community resident director. “We are thrilled to be hosting these informative sessions.”

“Wills and Estates” will be conducted by Mark L. Fortier, Esq., co-owner of Merrill, Hyde, Fortier & Youney, P.A., a general law practice located at 95 Water Street, Skowhegan, Maine. A native of Skowhegan, Mr. Fortier earned his JD from Vermont Law School in 1984. His practice includes the areas of real estate titles and closings, preparation of wills, administration of estates, guardianship/conservatorship of adults and minors, and adoptions.

“The Role of Physical Therapy in Improving Your Health” will be conducted by Linda Princiotta, PT, owner of Bright Physical Therapy. Ms. Princiotta is a Licensed Physical Therapist, with a BS in Physical Therapy from Quinnipiac University in Hamden, CT (1987). She’s a member of the American Physical Therapy Association; a Certified Clinical Instructor; a Certified Personal Trainer; and a member of the International Sports and Fitness Trainers Association. She lives in Pittson.

To get to Granite Hill Estates, take exit 109 from the south or 109B from the north off I-95 (Winthrop). Head west on Route 202. Take a left onto Edison Drive. GHE is on the right.

About Granite Hill Estates
GHE is a continuing care retirement community (CCRC) in the heart of the Kennebec Valley. Offering cottage homes and apartments, GHE provides a full complement of amenities and services, including an indoor heated swimming pool; a fully equipped fitness center; snow shoveling, lawn care, and exterior home maintenance; housekeeping; and appliance maintenance. GHE received its CCRC designation from the Maine Bureau of Insurance in November of 2004. And GHE provides a complete continuum of care, on campus, through MaineGeneral Health. For additional information, please visit www.granitehillestates.com.

SPRINGFIELD, OH–(Marketwire – July 6, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has closed its previously announced sale of 1,714,286 shares of common stock at $3.50 per share, resulting in gross proceeds to the company of $6.0 million. 

AdCare expects to receive net proceeds of approximately $5.4 million, after deducting underwriting discounts, commissions, legal fees and other offering-related expenses payable by the company. As previously announced, AdCare has granted a 30-day option to the underwriter to purchase up to an additional 15% of the shares offered, or 257,143 shares, to cover over-allotments, if any. 

AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes.

C.K. Cooper & Company acted as the sole manager for the public offering.

The shares were offered pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 4, 2010, which became effective on June 23, 2010. Copies of the prospectus supplement and accompanying base prospectus, which form a part of the effective registration statement, have been filed with the SEC and may be obtained from the SEC’s website at www.sec.gov or from C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus supplement and accompanying base prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include, among others, the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements. Except where required by law, AdCare undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

NEW YORK, NY–(Marketwire – July 6, 2010) –  In its ongoing effort to keep clients and key partners at the forefront of health promotion strategies in the workplace, Plus One hosted its annual Wellness Roundtable at the Cisco campus in San Jose, California today. Themed “Wellness Rx for the Future: Healthy Lifestyles as Medicine,” the event provided leaders from across the country the opportunity to explore how the most progressive companies and experts approach their employee wellness programs while achieving the greatest return on investment. 

Dr. Pam Hymel, Cisco’s Corporate Medical Director, led off the panel and discussed how Cisco executes on their vision for “enhancing the health and well-being of employees and their families leading to healthier, more fulfilling lives and greater productivity.” Through their comprehensive HealthConnections program, Cisco has created a vehicle to determine the most prevalent risk factors among their population, deliver targeted programs for engagement, and offer a single point of origin for family healthcare. 

Next, Dr. Kerry Olsen, Medical Director for Mayo Clinic’s Dan Abraham Healthy Living Center, reiterated the importance of the event’s theme that “exercise is medicine.” He shared how he and his team execute on their goal to “reach the hard to reach employees” and motivate them towards healthier lifestyles by focusing on the body, mind, and spirit. Through the Healthy Living Center’s utilization incentives, a direct correlation has been seen in risk factor reduction among Mayo’s population.

Ken Shachmut, Senior Vice President of Strategic Initiatives, Health Initiatives & Re-engineering for Safeway, closed the panel portion of the event. He shared how Safeway has been able to stand alone in holding their healthcare costs flat for the past five years through incentive based programs and more transparent employee communications. Comparing healthcare costs to Safeway’s core business, Ken asked attendees: “After you go grocery shopping, are you ever told you will receive a receipt after 30 days with the cost of purchase?”

Those attending the event took full advantage of the networking opportunities the setting provided, as well as toured the world class Cisco LifeConnections Health Center and Fitness Center managed by Plus One. Mike Motta, Plus One Co-Founder, President and Chief Executive Officer, hailed the success of the event: “The speakers today are testament to the power regular physical activity and comprehensive wellness programs can have on the health not only of a corporation’s employees, but their bottom line as well. I am proud that we were able to deliver an event like this for our clients and look forward to continuing to provide wellness solutions that deliver results.”

About Plus One
Plus One Health Management Inc. is a leading provider of comprehensive wellness solutions for corporations and other discerning organizations. From the design, development, and management of on-site wellness centers, to the creation and execution of results-focused employee wellness programs, to the five-star delivery of hospitality spa and fitness services, Plus One applies an integrated approach to individual and employee wellness. Clients include Fortune 500 companies, financial services firms, law partnerships, and world leaders in the media, biotechnology, energy, and pharmaceutical industries. Founded in 1986, today Plus One employs more than 1,500 professionals nationwide. For more information, please visit www.plusonehealthmanagement.com.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – July 6, 2010) –  International Stem Cell Institute (ISCI, http://www.iStemCelli.com) announced today a major breakthrough in stem cell therapy providing new hope for those suffering with Parkinson’s disease in the US and worldwide. The procedure using placenta stem cells is reversing current medical thinking which relies heavily on the use of drugs and surgery. This new advancement in medicine may be a significant step in the long sought after cure for Parkinson’s disease. Compared to prior medical procedures, ISCI’s proprietary stem cell therapy for Parkinson’s patients is showing immediate beneficial effects for many patients, and at a cost most families can afford.

Why Surgery Is Expensive and Risky
In one of the largest FDA approved randomized controlled studies, new Parkinson’s research shows motor functions in patients with very advanced symptoms can be improved with brain surgery. The study just published in the June 3 New England Journal of Medicine reports beneficial results from deep brain stimulation (DBS), an extreme and invasive surgical procedure which until now has been one of the most effective weapons in the war on the disease. However, International Stem Cell Institute (ISCI), a leading US based organization in stem cell therapies and regenerative medicine, believes Parkinson’s symptoms can be alleviated — almost to the point of full restoration — using placenta stem cells. Administering these stem cells, an easy and painless treatment, avoids the risks and costs of surgery. And unlike the wait for future drugs and clinical trials, stem cell treatment for Parkinson’s is not years off in the future but available to Parkinson’s sufferers right now.

Potential Drawbacks to DBS
One of the most serious adverse effects from DBS is intracranical hemorrhaging. The risk of hemorrhage closely correlates with the number of microelectrode passes used to determine the target location, with experts claiming it’s better to do more passes than less to be sure of where the electrodes are placed. “This kind of surgery requires many specialists, a Parkinson’s disease expert, a surgeon very skilled in stereotactic functional neurosurgery, a radiologist to precisely locate the target, and a physiologist for microelectrode placement and reading,” according to Rita Alexander, ISCI executive director. “Setting the stimulation parameters can take several hours, and more time is required for repeat evaluations to make certain the settings are correct. Clearly this procedure is very costly, risky, and can run $60,000 or more per patient. There may be negative consequences of targeting as well, including cognitive and psychological changes in patients.”

Treating Parkinson’s with Stem Cells Can Stop The Shaking, Restore Movement
“At ISCI we’ve successfully treated over 3,000 patients with many serious chronic diseases and we’re putting a huge focus on helping Parkinson’s patients. Our procedure represents a dramatic new advance in treating the disease, we’re seeing outstanding improved functions in advanced patients who can’t be satisfactorily controlled with drugs or high risk surgery,”  says Anderson. The therapeutic results from placental adult stem cell therapy is clearly effective at relieving the symptoms, and can provide a better quality of life for those in moderate to severe stages of the disease. ISCI is currently offering Parkinson’s patients the opportunity to undergo these innovative, less painful and less invasive medical treatments at a reasonable cost compared to brain surgery. “The families and individuals we work with are reporting truly amazing results,” Anderson maintains. “Some patients show amazing recovery from the nonstop shaking, regaining their balance and fluidity of motion. Their overall color is better and in some cases full range of movement is being restored.” Remarkably patients are recovering their ability to speak, to use handwriting and utensils, and showing decreasing problems with incontinence, swallowing and drooling. The International Stem Cell Institute is committed to providing innovative, long-term solutions for patients with chronic diseases ranging from cardiovascular disease and stroke, cerebral palsy, diabetes, autoimmune diseases such as RA and more.

Parkinson’s patients and their families are encouraged to contact ISCI directly at www.istemcelli.com/parkinsons.html

About ISCI (www.iStemCelli.com) ISCI is a leader in stem cell therapy and regenerative medicine dedicated to restoring vibrant health and quality of life for thousands of people with degenerative diseases around the world. Over 3000 patients have safely undergone stem cell treatments. The company has a global reach and is dedicated to the highest medical and ethical standards.

Disclaimer: Stem Cell Therapies offered for consideration by International Stem Cell Institute are not currently approved by the FDA and the treatments and procedures mentioned take place outside the USA.

Stem Cell Treatments are not a cure for any condition, disease or injury, nor a substitute for proper medical diagnosis and care. The information contained in this press release and ISCI’s written materials should not be considered medical advice. It is intended to be used for educational and information purposes only.

Click here to see all recent news from this company

KANSAS CITY, MO–(Marketwire – July 6, 2010) –  Academic institutions across the United States are playing a critical role in developing life-saving treatments, procedures and innovations, and must be supported by a public policy agenda designed to foster continued growth and investment, U.S. Secretary of Health and Human Services Kathleen Sebelius told a gathering of leaders from the public and private sectors here today. Friends of Cancer Research, Kansas Bioscience Authority, The University of Kansas Cancer Center, Ewing Marion Kauffman Foundation, and Council for American Medical Innovation convened today’s symposium titled The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results.

The program also included a moderated discussion with Dr. Francis Collins, director of the National Institutes of Health (NIH), and Dr. Margaret Hamburg, commissioner of the Food and Drug Administration (FDA) on agency perspectives to fostering innovation and increased collaboration. The discussion was moderated by former U.S. House Majority Leader and Chairman of the Council for American Medical Innovation, Richard Gephardt.

“This is a rare opportunity for anyone involved in cancer research and drug development,” said Roy A. Jensen, M.D., director of The University of Kansas Cancer Center. “To have so many key policy makers, academics, industry-leaders, and the non-profit community represented, discussing ways to drive new collaborations is extraordinary. As universities’ appetites for commercializing research grow and high-throughput platforms are increasingly adopted in public research programs, we seem to be seeing a new paradigm for drug discovery. We feel The University of Kansas Cancer Center is leading this effort in the new innovation ecosystem.” 

The day-long town hall, a result of collaboration between several like-minded organizations, explored drug development from the perspectives of thought-leaders from academia, government, industry and the nonprofit sector.

“This town hall, and the participation by scientific leadership at the highest levels, is an important step toward much-needed increased interagency collaboration,” said Dr. Ellen Sigal, chair, Friends of Cancer Research. “The proposals discussed today will accelerate the process to help get scientific breakthroughs to patients. Without collaboration among all agencies and academic centers, the full potential of biomedical research may be stifled.” 

“Discoveries from our academic labs fuel millions of jobs, spur small business, and promote innovation. The time is right for a fundamental re-examination of the changing role of academic institutions in the innovation process,” said Tom Thornton, president and chief executive officer, Kansas Bioscience Authority.

About Friends of Cancer Research

Friends of Cancer Research (Friends) is a cancer research think tank based in the Washington, D.C. area. Working with the entire cancer research and advocacy community, Friends pioneers innovative public-private partnerships, organizes critical policy forums, educates the public, and brings together key stakeholders to overcome the barriers standing between patients and the most promising cancer treatments.

About The University of Kansas Cancer Center

At The University of Kansas Cancer Center, we are more than an academic cancer center; we are a unique community-based cancer research and care partnership focused on one mission: eliminating the burden of cancer. The University of Kansas Cancer Center is transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our nationally accredited patient care program.

About the Ewing Marion Kauffman Foundation

The Ewing Marion Kauffman Foundation is a private nonpartisan foundation that works to harness the power of entrepreneurship and innovation to grow economies and improve human welfare.

About the Council for American Medical Innovation

The United States faces serious challenges to maintaining its leadership position in innovation. The Council for American Medical Innovation is bringing together leaders in research, medicine, public health, academia, education, labor, investment and business, who are working in partnership toward a national policy agenda aimed at preserving U.S. leadership in medical innovation. American medical innovators create millions of high-paying jobs, and their discoveries are integral in the fight to cure cancer and other illnesses. The Council for American Medical Innovation views leadership in medical innovation as a key part of America’s economic recovery, future prosperity and health.

About the Kansas Bioscience Authority

The KBA is a $581 million initiative that is advancing Kansas’ national bioscience leadership by building world-class research capacity; fostering the formation and growth of bioscience startups; supporting expansion of the state’s bioscience clusters; and facilitating industrial expansion and attraction.

Click here to see all recent news from this company

FOOTHILL RANCH, CA–(Marketwire – July 6, 2010) –  Medical Marijuana Inc (PINKSHEETS: MJNA) reports significant progress on staffing of The Hemp Network. President Don Steinberg states, “In the past, Bruce Perlowin and I have created a global network of over 125,000 agents in 50 countries. We have the experience in all aspects of running a global MLM. Now we are in this new, exploding industry with a team of Doctors, immunologists, PhDs, and world renowned nutritionists to round out the products division. We have top network marketers signed up who have already created hundreds of web sites to support this new company. Alexa has rated ‘The Hemp Network’ website in the top 2%. This is after only 2 months which shows the power of this new opportunity. Our proprietary MLM software is nearing completion with a pay plan that is revolutionary. To participate in daily conference calls which discuss the pay plan, upcoming events and exchange of ideas, call 218-339-3600 PIN: 321677. Calls are held Monday through Thursday at 6:00 PM (PDT), which we invite the public to attend.”

Bruce Perlowin, CEO, stated, “The opportunity to be involved in the 1^st hemp network marketing company in history in which an existing culture of numerous movements already exist who are passionate about hemp is irresistible. Hemp enthusiast movements include the medical marijuana movement, the marijuana legalization movement, the hemp movement itself, the health, wellness and anti-aging movement, the environmental movement and the green movement. These existing cultural creative movements all herald the wonders of hemp in their various areas and are all natural and highly motivated individuals ripe to participate in The Hemp Network.”

SOLUTIONS

Medical Marijuana Inc has developed a suite of solutions to deliver an efficient and secure infrastructure for the Medical Marijuana Industry which provides the tools to industry operators to effectively manage their business with the confidence that they are in full compliance.

MEDICAL MARIJUANA INC’S TURNKEY COLLECTIVE SOLUTION

Medical Marijuana Inc’s Turnkey Collective Solution ensures that collectives operate within the guidelines of all laws and regulations regarding the tracking of the cannabis from grow cycle to final distribution. By employing Medical Marijuana Inc’s closed loop, patent pending, tracking system, it can be shown to authorities and collectives alike that the source of their supply was an active member of the collective.

TAX COLLECTION

MJNA’s Stored Value Platform System provides verifiable solutions to manage the difficult task of revenue and taxation collection. The customers of the dispensary are issued a plastic debit card or medical revenue card. The ease of access to certifiably secure transactions lessens the risk of loss at each level of the transaction.

ABOUT MEDICAL MARIJUANA INC

Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding hemp and medical marijuana industries. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion, thus opening the door for safe and lucrative investment opportunities.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc to be materially different from the statements made herein.

NEW YORK, NY–(Marketwire – July 6, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical and biotechnology analytics company, has agreed to acquire a medical manufacturing company on multi-year terms that include benchmarks of a first year profit target range of $300,000-$600,000 and a second year target range of $600,000-$900,000. These numbers do not include the benefits of reinvestment by the company in (a) manufacturing, (b) existing company products, and (c) reduction of outstanding shares through company purchases. As a result, the medical manufacturing profits can potentially have a multiplier effect on the Company’s earnings per share.

The Company will continue to provide additional details as its acquisition strategy continues to unfold.

“We are pleased to provide this acquisition update showing the significant benefit that can accrue for the Company and stockholders,” said Alan Grofe, President.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  The Platelet Rich Plasma Treatment (PRP) is a non-surgical method that regenerates ligaments and treats chronic pain. Dr. Michael Cronin says, “During a Platelet therapy procedure the patient’s blood is drawn and put into a centrifuge which separates the plasma containing the essential platelets from the unneeded red blood cells. The PRP solution is carefully injected back into the patient’s injury area. The concentrated injection stimulates (mimics) the healing process through growth factors contained in the platelets.”

Dr. Michael Cronin was recently featured on the front cover of the Top Doctors of April 2010 in the April issue of Phoenix Magazine. Dr. Cronin is well known in Scottsdale for treating golfers for pain and injury recovery. “We often see multiple joint dysfunctions in our golfers. Our golfers are itching to get back on the course. Depending on the severity of the injury, utilizing Platelet Therapy, we can get them comfortable and moving again pretty quickly.”

Media attention first came to the revolutionary PRP treatment when Tiger Woods used it successfully to speed his recovery after surgery to his left knee. Woods was able to play in all four majors after four treatments of PRP. Tiger Woods has spoken openly about the success of his PRP Treatment in press conferences.

“PRP Treatment is no longer reserved for the elite,” states Dr Cronin. “We are having great success with our Golfers right here in Scottsdale.” In addition to sports injuries, PRP is useful for musculoskeletal pain, back pain, golfer’s elbow, rotator cuff tear, torn meniscus, strained tendons, ligaments and degenerated discs.

PRP Therapy is a major component of the healing process that Dr. Cronin prescribes. “If our Golfers want to be back on the course faster, we must attack the cause of the pain in a multi-faceted approach,” Cronin continues.

Michael Cronin, NMD, DAAPM, is a Diplomat of the American Academy of Pain Management and Founder of Southwest College of Naturopathic Medicine in Tempe, Arizona. “Treating pain effectively and achieving complete recovery is an important part of what we do here. PRP has given hope to those whom only a few years ago had very limited options to recovery,” says Dr. Cronin.

A short series of treatments is normal. The goal is to repair the injured areas, not just relieve the pain. The procedure does not create much discomfort and is recommended over the traditional use of cortisone injections.

For more info: www.plateletAZ.com

OXFORD, UK–(Marketwire – July 6, 2010) –

Mirada Medical Limited
(“Mirada” or “the Company”)

Mirada Medical Releases Casebook Software Upgrade for Medical Imaging Presentations

Oxford, UK and Ohio, US, 6 July 2010: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, today announces that it has released a software upgrade for Casebook (Casebook 1.1.), Mirada’s unique presentation tool for showing medical scans in Microsoft PowerPoint (“PowerPoint”).

Casebook 1.1 works as a plug-in to PowerPoint and uniquely supports fully triangulated multi-planar reconstruction (“MPR”) viewing of single or fused medical images. The new software may be used as a standalone program but also offers full integration with Mirada’s clinical products including XD3, Mirada’s powerful multi-modality image analysis application. Casebook 1.1 enables users to present case information derived from imaging studies clearly and professionally. The software also offers new image visualisation options and easy-to-use editing functions.

Commenting on today’s announcement, Chief Executive Officer, Hugh Bettesworth said: “Casebook provides an easy-to-use solution to a routine problem encountered by clinicians, researchers, academics, students and all who regularly show medical images using PowerPoint. Casebook comprehensively enhances these presentations by adding support for many of the image visualisation features which were previously the preserve of dedicated reading software.”

Casebook 1.1 is available to download free of charge from the Casebook website: www.mirada-casebook.com

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with an enhanced software package for the quantification of images typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada directly and also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.

IRVINE, CA–(Marketwire – July 5, 2010) –  EON Reality, the world’s leading interactive 3D software provider, today announced the release of EON Coliseum’s Medical Content Pack. This quick start package provides a variety of 3D environments, interactive 3D objects, PowerPoints and videos which help users to better understand the functionality and features of EON Coliseum. The online multiuser 3D interactive technology platform, EON Coliseum, provides realistic communication capabilities using rich media such as 3D worlds, slideshows, videos, avatars, voice, chat and interactive 3D objects virtually from anywhere in the world.

The focus on healthcare in today’s news brings up the key target question, how can we reduce costs while improving both quality and accessibility for the most important person in the equation — the patient? Technology innovation and enhanced collaboration are the keys to a new healthcare model that provides patients with the highest quality care and allows healthcare and medical organizations to achieve their targeted return on investment.

As well, there are many medical product options and configurations today which make it increasingly difficult to manage for the medical technology sales organization. On top of that, it is increasingly more challenging to demonstrate and train medical equipment for healthcare providers. There is a significant need to provide easy to understand patient education in a time and cost efficient manner that does not unnecessarily tie up physicians.

EON Coliseum can easily demonstrate many product options and configurations in full scale interactive 3D. As well, hands on training can be conducted safely in a virtual environment anytime anywhere in a cost effective way. Interactive 3D provides an easy to use tool where “what if” scenarios can be tested and exposes the expertise of top professionals to a larger student body.

About EON Reality
EON Reality, Inc. is the world’s leading interactive 3D visual content management and virtual reality software provider. EON’s solutions enable all organizations to more effectively visually communicate, collaborate and accelerate knowledge transfer. Industry leaders include Atlas Copco, Bechtel, Boeing, Bombardier, Hon, Intel, Lexus, Lufthansa — Teknik, Peterbilt, Samsung, Siemens Medical, Suzuki, Toyota and Whirlpool use EON solutions to enhance the interactive user experience to effectively increase sales, better communicate product functionality and decrease the cost of service, training and technical support. For further information, visit www.eonreality.com.

Click here to see all recent news from this company

FORT LAUDERDALE, FL–(Marketwire – July 2, 2010) –  eDiets.com, Inc. (NASDAQ: DIET), a leading provider of convenient at-home diet, fitness and healthy lifestyle solutions, today announced that on June 28, 2010, it received notice from The Nasdaq Stock Market that the minimum bid price of the Company’s common stock closed below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Nasdaq’s listing rules (Rule 5550(a)(2)).

In accordance with the rules, the Company has 180 calendar days, or until December 27, 2010, to regain compliance. If at any time before that date the bid price of the Company’s common stock closes at $1.00 per share or more for at least 10 consecutive business days, Nasdaq will provide written notification that the Company complies with the rules (Rule 5810(c)(3)(A)).

If compliance is not achieved by December 27, 2010, the Company will be eligible for an additional compliance period of 180 days provided that it meets The Nasdaq Capital Market initial listing criteria (Rule 5505), with the exception of the bid price requirement. If the Company is not eligible for an additional compliance period, Nasdaq will provide written notification that the Company’s securities will be delisted. At that time, the Company may appeal Nasdaq’s determination that the Company’s common stock will be delisted from The Nasdaq Capital Market.

About eDiets

eDiets.com, Inc. is a leading provider of personalized nutrition, fitness and weight-loss programs. eDiets currently features its award-winning, fresh-prepared diet meal delivery service as one of the more than 20 popular diet plans sold directly to members on its flagship site, www.eDiets.com. The company also provides a broad range of customized wellness and weight management solutions for Fortune 500 clients. eDiets.com’s unique infrastructure offers businesses, as well as individuals, an end-to-end solution strategically tailored to meet its customers’ specific goals of achieving a healthy lifestyle. For more information, please call 310-954-1105 or visit www.eDiets.com.

Safe Harbor Statement
Statements which are not historical in nature are forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements. These risks and uncertainties include, among others, that we will not be able to obtain sufficient and/or acceptable outside financing (when and if required); changes in general economic and business conditions; changes in product acceptance by consumers; a decline in the effectiveness of sales and marketing efforts; loss of market share and pressure on prices resulting from competition; significant investments in our technology platform, marketing plans, and product development to remain competitive with other online providers of healthy living and weight loss plans, many of which may be found to offer superior and more varied features than our plans and may also be offered for free; volatility in the advertising markets; any delay, disruption, or suspension of our supply of prepared meals from our vendor; changes in consumer preferences and discretionary spending; product liability and other risks from the sale of ingested products; regulatory actions affecting our marketing activities; and the outcome of litigation pending against us. For additional information regarding these and other risks and uncertainties associated with eDiets.com’s business, reference is made to our Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed from time to time with the Securities and Exchange Commission. All forward-looking statements are current only as of the date on which such statements are made. We do not undertake any obligation to publicly update any forward-looking statements.

JOHANNESBURG, SOUTH AFRICA–(Marketwire – July 2, 2010) –  www.rothmanresearch.com — Healthcare spending in the U.S. accounts for close to 16% of the nation’s GDP and according to estimate of every dollar disbursed on health care 31% is allocated to hospital care. There are over 6000 hospitals, government or privately administered, scattered throughout the U.S. territories, employing over 4.5 million workers and generating an overall yearly revenue of about $700 billion. Accounting for almost 2% of the market, Community Health Systems Inc. (NYSE: CYH) is regarded as the biggest for-profit general healthcare services in the country.

*Free downloadable research reports on Health Management Associates Inc. and Community Health Systems Inc. are available by signing up now at http://www.rothmanresearch.com/article/hma/23652/Jul-02-2010.html or http://www.rothmanresearch.com/article/cyh/23653/Jul-02-2010.html

A major milestone in the industry which also impacted the whole of the healthcare sector was achieved in March 2010 when the healthcare reforms were passed as law. With this new law additional patients in their millions (between 31 to 32 millions) will now be covered by health insurance. The Patient Protection and Affordable Care Act also encourage healthcare institutions to start the creation of a universal database of electronic medical records. Mercy Health Systems is amongst those which have already started experimenting with this new system. 

www.rothmanresearch.com is a source for investors seeking free information on Hospitals industry; investors are encouraged to sign up for free at http://www.rothmanresearch.com/index.php?id=6&name=Register.

Hospitals in the U.S. are very close to the monopoly concept, and one of the key reasons why hospital operators like Health Management Associates Inc. (NYSE: HMA) can achieve this kind of regional dominion is through consolidation. Recently, Health Management Associates has announced the acquisition of 60% controlling shares in three Shands Healthcare hospitals.

Companies looking for additional media or advertising services can call Blue Chip IR at 1-917-267-8836

About Rothman Research
Rothman Research brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.

CHICAGO, IL–(Marketwire – July 1, 2010) –  GoHealthInsurance.com, an online health insurance marketplace, recently launched www.GoHealthExchange.com as an educational resource for health reform information and the use of technology with the implementation of health care reform.

GoHealthExchange.com provides an overview of the future of health insurance and the importance of providing consumer-driven tools and information. With health care reform, the convergence of technology, information and health insurance agents will come together to provide the ultimate consumer experience.

“Providing an in-depth resource on health care reform and changes to health insurance policies will help make the next few years an easy transition for consumers. Access to information and technology will be critical for the success of reform,” said Michael Mahoney, Director of Consumer Markets at GoHealthInsurance.com.

Recently, the new health reform government site, HealthCare.gov, was launched to provide a great resource for individuals and businesses looking for health care reform information. The consumer-driven site will help provide individuals and businesses a go-to place to find solutions regarding health reform.

Many consumers have been confused about health care reform and the changes to health insurance policies. Sites like GoHealthExchange.com and HealthCare.gov will help provide health coverage answers and solutions for many Americans.

Similar to the vision of HealthCare.gov, GoHealthInsurance.com currently offers interactive tools to help all Americans compare, apply and buy health insurance online. For example, on GoHealthInsurance.com, consumers can view health plans side-by-side from leading insurance companies including Aetna, many Blue Cross and Blue Shield companies, UnitedHealthOne and more.

Consumers can use the tools at GoHealthInsurance.com absolutely free at www.gohealthinsurance.com.

About GoHealthInsurance

GoHealthInsurance.com makes buying health insurance simple. GoHealthInsurance explains health coverage options in plain English, provides free health insurance quotes, connects shoppers with local agents, and helps consumers choose plans that meet their health and budget needs.

Click here to see all recent news from this company

OMAHA, NE–(Marketwire – July 1, 2010) –  Avantas is proud to announce a new agreement to provide the healthcare scheduling software, Smart Square, to Champlain Valley Physicians Hospital (CVPH) Medical Center in Plattsburgh, NY.

Smart Square is a comprehensive labor management tool designed specifically for healthcare. Intuitive, flexible, and highly configurable, it can be utilized system-wide in both nursing and non-nursing units. 

With Smart Square, organizations can effectively schedule core staff and proactively manage contingency staff against forecasted patient demand, while elevating labor management to an enterprise business initiative.

Interfacing seamlessly with 3^rd party Time/Attendance, Payroll and HRIS systems, Smart Square provides real-time analytics and dashboards that identify opportunities to adjust staffing levels, manage incidental worked time, and prevent waste. Additionally, the Software as a Service (SaaS) platform reduces costly internal infrastructure and enables access to all the tools within the application anytime, from anywhere. 

“The only certainty healthcare organizations can rely upon in these changing times is the ongoing pressure to keep productivity on target,” said Chris Fox, Avantas’ Senior Vice President of Growth & Innovation. “Smart Square enables hospitals to better manage their resources by making proactive, cost-conscious staffing decisions that meet the needs of their patients. With Smart Square, CVPH is poised to flourish while providing the exceptional care for which they are known.”

CVPH is a 391-bed facility recognized as a leader in providing quality care and health and wellness services to North Country residents in upstate New York. “CVPH is excited to be partnering with Avantas for the implementation of Smart Square,” says Rosemary Reif, Associate Vice President of Patient Services at CVPH. “After researching other automated staffing and scheduling systems, we are confident this is the product for us — providing the sophistication, expertise, and support to streamline and maximize our employee resources!” Also point on the project from CVPH are Julie Brunell, Associate Vice President of Patient Services and Rhonda Kowalowski, Office Supervisor-Patient Services.

Discover the Smart Square difference by scheduling a web demo: 888-338-6148.

About Avantas

Avantas (www.avantas.biz) is an Omaha, Nebraska-based company devoted to serving the healthcare industry. By combining advanced technology with evidence-based methodologies, Avantas delivers immediate ROI and long-term savings by helping healthcare organizations realize continual improvement with regard to healthcare scheduling and staffing.

Click here to see all recent news from this company

KANSAS CITY, MO–(Marketwire – July 1, 2010) –  Internal Health Specialist and Overland Park Chiropractor Dr. Robert Patterson recently evaluated the benefits of working with Jennings Social Media Marketing.

Watch Dr. Patterson review social media marketing:
http://www.youtube.com/user/MichelleJPRA

Dr. Patterson explains that in a busy practice it is difficult to just get through his emails every day, let alone try to deal with essential parts of marketing such as Facebook, Twitter or the blog. “Jennings Social Media Marketing gives me the tools I need to see how much traffic we have to our blog, how many followers we have on Twitter, how many people signed up for our e-newsletter and how many hits we get on our website. I can see the growth of these areas with my own eyes. Valerie Jennings, CEO of Jennings Social Media Marketing, helps me manage all of the marketing, advertising and public relations. It is important to have someone like Valerie, who is high energy, to push me and give me deadlines,” said Patterson.

Patterson said that Jennings gives him confidence that all of the marketing, advertising and public relation needs for his practice will be taken care of. “Jennings Social Media Marketing is an extension of my staff. They work hard to deliver measurable results. Our relationship with Jennings will definitely be a long-term one,” said Dr. Patterson.

Jennings Social Media Marketing is a full service company that utilizes the art of online storytelling with the science of measuring quantifiable results. Jennings creates comprehensive social media marketing and Web advertising strategies from website design and development to viral videos. The company represents publicly traded to medium-sized businesses across the U.S. and overseas including technology, sports, sustainability, entertainment, travel, financial, health care and real estate.

Dr. Robert Patterson is the founder of Overland Chiropractic and has been practicing for more than 20 years in the Kansas City area. In 2007, his clinic became only one of approximately 300 Creating Wellness centers located in the United States, Canada and New Zealand. Patterson is a graduate of Cleveland Chiropractic College (Kansas City), class of January 1988 and has specialized in the treatment of low back and leg pain for much of his career. Patterson is one of only three certified doctors in Kansas in Cox Flexion Distraction (decompression) manipulation. Most recently, he received Certification as an Internal Health Specialist through Logan College of Chiropractic.

Click here to see all recent news from this company

CAMDEN, NJ–(Marketwire – July 1, 2010) –  Close on the heels of another major award from the National Institutes of Health (NIH), the Coriell Institute has announced its receipt of a five-year, $6-million NIH contract to manage the National Institute on Aging (NIA) Aging Cell Repository.

“Our long-standing expertise in the biobanking arena has been a decisive factor in maintaining major contracts such as the NIA Cell Repository,” said Coriell President and CEO, Michael F. Christman, Ph.D.

Coriell has overseen the Aging Cell Repository since its establishment in 1974, repeatedly outshining the competition to house this vital resource and distribute high-quality biomaterials for research purposes. The Repository, which facilitates cellular and molecular research studies on the mechanisms of aging and the degenerative processes associated with it, contains more than 2,000 cell lines from individuals with premature aging disorders, Alzheimer’s disease, and samples from persons of great age (90+ years).

“Diseases like Alzheimer’s and Parkinson’s ravage our seniors, weigh on their loved ones and drain patients of financial resources,” said U.S. Senator Robert Menendez. “This an investment that will assist research to treat and defeat these diseases, while lowering the costs associated with them. Coriell is helping to lead the way, once again showing how New Jersey is the innovation state.”

Scientists in more than 40 countries have utilized these vital biomaterials, resulting in the publication of more than 1,000 scientific papers describing aging-related research discoveries. These samples have been used in the identification of many disease genes, including the gene for Hutchinson Gilford Progeria Syndrome, a rare, genetic disease causing characterized by dramatic, rapid appearance of aging beginning in childhood.

With this award, Coriell is responsible for selecting, establishing, characterizing, documenting and storing new aging-related cell lines for research. Additionally, Coriell will bank induced pluripotent stem cell (iPSC) lines — cells produced by genetically reprogramming specialized cell types, like skin cells, into cells with the ability to turn into any human cell type.

“Coriell will be integrating a revolutionary technology, iPSCs, into the Repository collection to support the study of aging-related diseases. This effort will promote discovery around the causes and potential cures for devastating diseases such as Parkinson’s disease,” said Margaret Keller, Ph.D., Principal Investigator of the NIA contract. “The future holds great promise for the use of iPSCs in regenerative medicine and we are taking the first step to understand this potential.”

Since its establishment in 1953, Coriell has served the scientific community by maintaining the world’s leading cryogenic biobanking facility, distributing its more than 745,000 unique samples — encompassing cell lines, DNA, RNA, plasma, and more — to researchers in sixty-five nations. Through contracts such as the National Institutes on Aging, Coriell is able to support worldwide research initiatives with the ultimate goal of improving human health.

About Coriell
Coriell Institute for Medical Research (www.coriell.org) is an internationally known, non-profit, biomedical research institution headquartered in Camden, NJ, contiguous with the Cooper University Hospital Health Sciences Campus. Founded in 1953, Coriell is the world’s leading biobank resource for biological materials and home of the Coriell Personalized Medicine Collaborative^® (CPMC^®) research study, a forward-looking project aimed at understanding the utility of genome-informed medicine and identifying genetic variants associated with common complex disease and variation in drug response (http://cpmc.coriell.org).

About NIA
The NIA leads the federal effort supporting and conducting research on aging and the medical, social and behavioral issues of older people. For more information on research and aging, go to www.nia.nih.gov.

The NIH — the nation’s medical research agency — includes 27 institutes and centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

HOUSTON, TX–(Marketwire – July 1, 2010) –  PerioHealth^™ Professionals, also known as Houston’s Smile Engineers^™, are a team of dedicated dental specialists who specialize not only in the prevention, diagnosis, and treatment of periodontal disease, also known as gum disease, but also in the placement of dental implants, a permanent replacement for lost or damaged teeth.

The principals of PerioHealth Professionals, Michael K. McGuire, DDS and E. Todd Scheyer, DDS, MS, practicing in Houston for a combined total of 40 years, are world-renowned experts when it comes to dental implants. Their implant expertise has helped thousands of patients from Houston and across the nation, enabling them to eat solid foods, advance their careers, find romance, and enhance their overall quality of life.

Both are board-certified periodontists, and each has extensively lectured on, written about, and conducted research on the latest advances in dental implants and related surgical procedures. They are considered pioneers in an advanced form of implant treatment called “guided implant surgery,” which uses computer technology and 3-D digital X-rays to ensure the most precise implant placement possible.

“There is no doubt that dental implants are among the most significant advances in dentistry, with guided implant surgery helping to make the placement and success of same-day implants more predictable, “says Dr. McGuire. “However, the marketing claims of some high-volume implant practices lead consumers to believe that implants can be placed quickly in all cases, and this is not always true.”

PerioHealth patients, according to Drs. McGuire and Scheyer, frequently come in with severe gum disease and bone loss. “As periodontists, we are uniquely qualified to assess the individual patient’s gums and underlying bone structure to determine if they can support and sustain a dental implant,” explains Dr. Scheyer. “If not, we can perform preliminary surgical procedures, including tissue grafting and bone regeneration, to help rebuild the strong foundation needed to bear the load of an implant during chewing, etc.” 

Other factors that Drs. McGuire and Scheyer take into consideration when evaluating each dental implant candidate include the following:

• The age of the patient
• How long the tooth has been missing
• Pre-existing periodontal disease
• Overall patient health
• Individual’s rate of healing
• Whether the implant is in the front or back of the mouth
• Whether implants can be splinted together

“There’s no doubt that dental implants, when placed correctly and monitored properly, can dramatically improve a person’s smile, quality of life, and overall health, and last for a lifetime,” comments Dr. McGuire. “However, to ensure all of these patient benefits, we at PerioHealth Professionals believe a personalized approach to evaluation, treatment, and follow-up is required.”

About PerioHealth^™ Professionals

Known as Houston’s very own “Smile Engineers^™,” PerioHealth^™ Professionals has established itself as the most trusted source for accurate information and expert treatment regarding a variety of relevant topics within the dental field, including oral/systemic health links, single and multiple-site implants, tissue engineering, periodontal plastic surgery, and guided implant surgery. 

Established in 1979, PerioHealth Professionals is led by Michael K. McGuire, DDS and E. Todd Scheyer, DDS, MS. Both are board-certified periodontists who have dedicated their professional lives to the practice of periodontics, the organized leadership of the profession, and educating fellow dentists and patients alike on the various aspects of proper periodontal care, including:

• Dental implants
• Tissue grafting to reduce gum recession and bone loss
• Periodontal procedures to correct damaged or extracted teeth
• Prevention, identification, and treatment of periodontal disease
• Recontouring of the teeth and gums
• Bone regeneration therapy
• Education and clinical research

PerioHealth Professionals’ “personalized care” philosophy is what drives the independent periodontal practice to best serve its patients by not being locked into a specific treatment protocol or dental implant product line. Instead, PerioHealth Professional team members are firm believers in “patient-driven dentistry,” which means each periodontal and implant case is treated with optimum, personalized care from the initial evaluation and treatment to long-term follow-up and maintenance. 

Click here to see all recent news from this company

MADISON, WI–(Marketwire – July 1, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that it will release its 2010 second quarter financial results on Thursday, July 29, 2010 at 3:00 p.m. CDT.

TomoTherapy will hold an investment community conference call on Thursday, July 29, 2010 beginning at 4:00 p.m. CDT. Fred Robertson, M.D., CEO, and Thomas Powell, CFO, will review second quarter performance and discuss the company’s strategies. To join the conference call, dial 1-800-260-8140 (international 1-617-614-3672) and enter passcode 35309628. A replay of the conference call will be available at 7:00 p.m. CDT on July 29, 2010, through 11:59 p.m. CDT on August 5, 2010. To access the replay, dial 1-888-286-8010 (international 1-617-801-6888) and enter passcode 64325104.

For individual investors, a live Webcast of the conference call will be available on the Investor Relations page of TomoTherapy.com. Institutional investors can access the Webcast through a password-protected site, www.streetevents.com. An archived Webcast of TomoTherapy’s conference call will be available for two weeks.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, Hi·Art, TomoHD, TomoMobile and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

ALBUQUERQUE, NM–(Marketwire – July 1, 2010) –  The nation’s first scientific study on the effects of wood smoke in smokers shows that wood smoke is associated with chronic obstructive pulmonary disease (COPD), and has identified a link that increases the risk for reduced lung function in cigarette smokers. That exposure to wood smoke causes COPD was previously found to be common in women in developing countries, but has not been recognized as being a hazard at concentrations generally found in developed countries. 

The objective was to evaluate the risk of wood smoke for COPD in a population of smokers in the United States, and whether non-hereditary changes of DNA that were detected in sputum samples of these patients were correlated to the disease of COPD as shown by the destruction of lung function. The association between wood smoke and reduced lung function was stronger among current cigarette smokers, non-Hispanic whites and men.

Lead investigators at Lovelace Respiratory Research Institute (LRRI) in New Mexico, the only dedicated respiratory research center in the US, in collaboration with the University of New Mexico School of Medicine and the University of Colorado at Denver, conducted the study which was financed by the appropriation from the Tobacco Settlement Fund, and from the National Institutes of Health (NIH). The findings were recently published in the American Journal of Respiratory Critical Care Medicine, a publication by the American Thoracic Society.

Yohannes Tesfaigzi, Ph.D., Senior Scientist at LRRI based in ABQ, NM and lead investigator, said, “The findings are significant and timely because it shows that there are many factors that reduce lung function in the world today.” Tesfaigzi continued, “Our findings suggest that smokers of cigarettes who are exposed to wood smoke increase their risk of having reduced lung function.”

For the research, a cross sectional study of 1,827 subjects were drawn from the Lovelace Smokers’ Cohort, a predominantly female cohort of smokers that is unique with its high percentage of Mexican Hispanic participants. The wood smoke exposure was self-reported. The research included measuring air entering and leaving the lungs, airflow obstruction and chronic bronchitis. Also explored were modification of wood smoke exposure with current cigarette smokers, ethnicity, sex, and the relationship with lung cancer-related genes on COPD. 

Robert W. Rubin, Ph.D., CEO of Lovelace Respiratory Research Institute, said, “Many people use wood smoke as a major heating source and also smoke cigarettes, and this research proves that it can be a very unhealthy combination.” Rubin continued, “With the legitimate concern to find alternative energy and heating methods in the world, we need more research of this kind to make certain that we do not add to the many factors in the air we breathe that will contribute to the destruction of lung function.” 

About Lovelace Respiratory Research Institute

The Lovelace Respiratory Research Institute (LRRI) is a private, biomedical research organization dedicated to improving public health through research on the prevention, treatment and cure of respiratory disease. LRRI is committed to curing respiratory diseases through research aimed at understanding their causes and biological mechanisms; assessing and eliminating exposures to respiratory health hazards; and developing improved therapeutics, vaccines, and diagnostics. LRRI is based in Albuquerque, New Mexico, employs 1100 people, and is a $125 million company. www.lrri.org

Click here to see all recent news from this company

YOQNEAM, ISRAEL–(Marketwire – July 1, 2010) –  Given Imaging Ltd (NASDAQ: GIVN), a leader in capsule endoscopy and specialty GI diagnostics, today announced that the first in-human study analyzing remote magnetic manipulation of a PillCam video capsule was published in the June 2010 edition of Gastrointestinal Endoscopy, the journal of the American Society for Gastrointestinal Endoscopy, which validates the potential of magnetic maneuvering of the PillCam capsule endoscope. Led by Dr. Paul Swain of the Imperial College, London, United Kingdom, and sponsored by the nano-based capsule endoscopy with molecular imaging and optical biopsy (NEMO) consortium led by Given Imaging, the study aimed to assess the efficacy of remote magnetic manipulation in the esophagus and stomach by simultaneously recording the capsule’s positions and movements with the orientation and movement of the external handheld magnet.

“This study demonstrated two things: 1] we can maneuver capsule in humans and 2] that the procedure is painless. We believe that these results underscore the value of conducting additional clinical studies in humans,” said Dr. Paul Swain of the Imperial College, London, United Kingdom. “Remote manipulation may improve diagnostic accuracy and is essential for the future development of remote controlled therapy by video capsules.”

Researchers modified a PillCam^® COLON capsule to include rare earth magnetic materials and to replace the usual magnetic on/off switch with a thermal switch. An external paddle-shaped magnet was used to manipulate the capsule remotely, and Given Imaging’s RAPID^® RealTime viewer captured capsule images. Additionally, a high-definition video-gastroscope was used to observe the capsule in the esophagus and stomach, and a room video camera recorded the scene and hand movements of the endoscopist to allow coordinated time imaging of the movement of the external magnet with movements of the capsule inside the stomach and esophagus.

“As the pioneers of capsule endoscopy, Given Imaging is committed to exploring new ways to make both diagnoses and therapeutic interventions in the GI tract less invasive and more effective for patients,” said Homi Shamir, president and chief executive officer, Given Imaging. “Our relationship with the NEMO Consortium exemplifies how productive a true partnership between industry and the medical community can be at finding new ways to improve patient care.”

The exam was performed in the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA, by Richard I. Rothstein, MD and Paul Swain of the Imperial College, London, UK in cooperation with Given Imaging. IBMT, or the Fraunhofer Institute for Biomedical Engineering, St. Ingbert, Germany, provided the external paddle-shaped magnet under the direction of Frank Volke, PhD.

About Given Imaging Ltd.
Since 2001, Given Imaging has advanced gastrointestinal visualization by developing innovative, patient-friendly tools based on its PillCam^® Platform. PillCam^® capsule endoscopy provides physicians with natural images of the small intestine via PillCam^® SB, the esophagus through PillCam^® ESO and the colon with PillCam^® COLON [PillCam COLON is not cleared for use in the USA]. The PillCam^® capsules are miniature video cameras that patients ingest. Given Imaging’s other capsule products include Agile™ patency capsule, to verify intestinal patency, and Bravo^®, the only wireless, catheter-free, 48-hour pH test commercially available for pH testing to assess gastroesophageal reflux disease (GERD). Given Imaging’s products use cutting-edge, wireless technology and advanced software to enable gastroenterologists to visualize diseases of the esophagus, small bowel and colon. All Given Imaging products allow patients to maintain normal activities. In April 2010 Given Imaging acquired Sierra Scientific Instruments, the leading provider of specialty GI diagnostic solutions and pioneer of high-resolution manometry for assessing gastrointestinal motility. Sierra Scientific is now a wholly-owned subsidiary of Given Imaging. Given Imaging’s headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia and Singapore. For more information, please visit www.givenimaging.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as “may,” “anticipates,” “estimates,” “expects,” “intends,” “plans,” “believes,” and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to successfully complete any necessary or required clinical studies with our products, (3) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (4) our success in implementing our sales, marketing and manufacturing plans, (5) the level of adoption of our products by medical practitioners, (6) the emergence of other products that may make our products obsolete, (7) lack of an appropriate bowel preparation materials to be used with our PillCam COLON capsule, (8) protection and validity of patents and other intellectual property rights, (9) the impact of currency exchange rates, (10) the effect of competition by other companies, (11) the outcome of significant litigation, (12) our ability to obtain reimbursement for our product from government and commercial payors, (13) quarterly variations in operating results, (14) the possibility of armed conflict or civil or military unrest in Israel, (15) the impact of global economic conditions, (16) our ability to successfully integrate acquired businesses, (17) changes and reforms in applicable healthcare laws and regulations and (18) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as “Risk Factors,” “Cautionary Language Regarding Forward-Looking Statements” and “Operating Results and Financial Review and Prospects” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2008. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company’s ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

NEW YORK, NY–(Marketwire – July 1, 2010) –  Allied Healthcare International Inc. (NASDAQ: AHCI) (AIM: AHI) (“Allied”), a leading provider of flexible healthcare staffing services in the United Kingdom, announces today that it has requested the cancellation of admission to trading of its depository interests on the Alternative Investment Market (AIM) of the London Stock Exchange. Cancellation will become effective as of 7:00 a.m., U.K. time, on August 20, 2010 (the “Effective Time”). The depository interests will trade on AIM through the close of business on August 19, 2010. Each depository interest represents one share of common stock of Allied.

The shares of common stock of Allied will continue to trade on the Nasdaq Global Select Market after the cancellation of admission to trading on AIM of the depository interests.

Allied’s depository interests were admitted to trading on AIM in December 2005 in the expectation (among other reasons) that the quotation would provide an additional source of liquidity for investors who wished to own an equity position in Allied. Allied also anticipated that the admission to trading on AIM of its depository interests would enable it to access the capital markets in the U.K. and provide it with an enhanced ability to undertake acquisitions. However, there have never been more than ten holders of depository interests at any one time and there are currently only eight holders of depository interests. As a result, Allied has not realized the benefits it anticipated at the time of admission. In light of this and the costs and additional regulatory burdens associated with continued admission of its depository interests, the board of directors of Allied has determined to request the cancellation of admission to trading on AIM of its depository interests as of the Effective Time.

At the Effective Time, the Deed that established the depository interests will be terminated and the depository interests will cease to exist. Prior to the Effective Time, holders of depository interests will be able to trade their depository interests on AIM or transfer their depository interests into an identical number of shares of common stock of Allied. In the event that any holder of depository interests has not transferred its depository interests into shares of common stock prior to the Effective Time, at the Effective Time the depository will cause any holder of then-outstanding depository interests to be registered on the stockholders’ list of Allied as a holder of an identical number of shares of common stock of Allied. Allied will send to the current holders of depository interests a letter explaining their options for converting depository interests into shares of common stock.

About Allied Healthcare International Inc.

Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of over 110 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

Forward-Looking Statements

Certain statements contained in this news release may be forward-looking statements. These forward-looking statements are based on current expectations and projections about future events. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements include: general economic and market conditions; Allied’s ability to continue to recruit and retain flexible healthcare staff; Allied’s ability to enter into contracts with local government social services departments, NHS Trusts, hospitals, other healthcare facility clients and private clients on terms attractive to Allied; the general level of demand for healthcare and social care; dependence on the proper functioning of Allied’s information systems; the effect of existing or future government regulation of the healthcare and social care industry, and Allied’s ability to comply with these regulations; the impact of medical malpractice and other claims asserted against Allied; the effect of regulatory change that may apply to Allied and that may increase costs and reduce revenues and profitability; Allied’s ability to use net operating loss carry forwards to offset net income; the effect that fluctuations in foreign currency exchange rates may have on our dollar-denominated results of operations; and the impairment of goodwill, of which Allied has a substantial amount on the balance sheet, may have the effect of decreasing earnings or increasing losses. Other factors that could cause actual results to differ from those implied by the forward-looking statements in this press release include those described in Allied’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. Allied undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 

TAMARAC, FL–(Marketwire – July 1, 2010) –  AcuMedSpa Holdings, Inc. (PINKSHEETS: AMSZ), a provider of Medical Aesthetic, Spa and Acupuncture services, would like to address an erroneous filing made to raise the authorized shares.

A filing dated June 25, 2010 was made with the state of Nevada to raise the authorized shares of AcuMedSpa from its current 150 million shares to 300 million shares. This action was done erroneously and was never intended to be filed. AcuMedSpa has rescinded the incorrect filing and expects the State of Nevada website to reflect this action shortly. The correct authorized shares total should be 150 million shares.

The company does not have the authority to raise the authorized shares without majority shareholder approval. Recently AcuMedSpa reformed its share structure by reducing both the authorized shares and the outstanding shares. These changes were intended to give all major decision making power to the shareholders. Any significant share structure decisions such as raising the authorized shares, share issuances, and stock splits of any kind etc. now require the consent of a majority of shareholders by proxy vote.

“Obviously raising the authorized shares after just having lowered them was not by design,” stated AcuMedSpa Holdings President Gregory Antoine. “Just last week we reiterated in our press releases that moves like this cannot be done without consent from our shareholders. This was a regrettable internal communication error on our part. Our commitment to our shareholders has never wavered and we will continue to press forward in our efforts to continue building a strong company.”

Please follow our progress on twitter: http://twitter.com/acumedinc

For additional info please visit our website: http://www.acumedspa.com/

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements as a result of various factors, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AcuMedSpa Holdings, Inc. takes no obligation to update such statements.  

ALEXANDRIA, VA–(Marketwire – June 30, 2010) –  The American Diabetes Association does not have official position favoring or recommending against specific drugs that are approved by the FDA to lower glucose. The 2009 consensus statement on medical management of hyperglycemia in type 2 diabetes does not reflect official position of the ADA but rather the expert opinion of the authors of the paper.

Recently, additional information regarding the cardiovascular safety of rosiglitazone was reported, with some analyses suggesting a possible increase in risk and others supporting the drug’s safety. This information as well as past reports of a potential increase in the risk of CVD is being reviewed by the FDA. The Association’s staff and volunteer leadership are also reviewing the information in the public domain and await further information from the FDA. Until further information is provided, patients and health care professionals should continue to recognize that multiple classes of drugs, often with more than one agent per class, are available to maintain glucose control in type 2 diabetes.

The decision whether or not to use any medication must remain that of the treating physician in direct discussion with their patients. As additional information becomes available, the Association will provide detailed updates for both health care professionals and patients with diabetes. Patients should continue taking all currently prescribed medications unless otherwise informed by their health care team.

The American Diabetes Association is leading the fight against the deadly consequences of diabetes and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

NEW YORK, NY–(Marketwire – June 30, 2010) –  Stimulus incentives designed to spur hospitals and physicians to use EMR systems are among several factors that will drive growth of handheld devices in healthcare, according to a new report from healthcare market research publisher Kalorama Information. The report, “Handhelds in Healthcare: The World Market for PDAs, Tablet PCs, Handheld Monitors & Scanners,” indicates that handheld device sales for healthcare use reached $8.2 billion globally in 2009 and are expected to increase to seven percent for the next five years as physicians and hospitals purchase new IT systems. 

“The ARRA incentives for electronic medical records do not specifically reimburse doctors for devices,” said Bruce Carlson, Publisher of Kalorama Information. “But they are getting healthcare organizations to think about IT purchases, and they are helping to make the argument for better electronic data entry, something that we think will lead to increased sales for devices used to enter data.”

Other factors are driving the expansion of this market, including a growing and aging population, a shortage of qualified medical professionals, cost restraints, and medical error reduction measures, according to the report. The propensity of doctors and nurses to use the devices is also driving sales. 

“Healthcare workers need to be mobile, and so PDAs and monitoring devices have long been a good fit,” said Carlson.

The report looks at all handheld devices and makes specific forecasts for each category. Patient monitoring devices account for the largest share of sales in the handheld market, largely due to the range of products available, the number of conditions requiring monitoring, and increasing demand for essential monitoring products in portable sizes, such as ultrasound and ECG. Administrative devices have exploded over the last five years with the growing use of PDAs, smartphones, and tablet PCs taking hold in the healthcare industry. Advances in technology and the continued benefits provided by handheld devices are a significant factor in driving this market.

Competitors supplying new technologies to hospitals are mainly large, established healthcare companies, often working in conjunction with other information technology companies on an entire system. Some of the top companies offering handhelds are Research in Motion, GE Healthcare, Global Media, Medtronic, Omron, Siemens Healthcare, Socket Mobile, Inc. and Welch Allyn.

“Handhelds in Healthcare: The World Market for PDAs, Tablet PCs, Handheld Monitors & Scanners” provides profiles of these competitors, discusses trends in handheld technology in healthcare and forecasts the market for these devices. The report can be found at:
http://www.kaloramainformation.com/redirect.asp?progid=79304&productid=2703662.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

MUNDELEIN, IL–(Marketwire – June 30, 2010) –  To help homecare providers improve patient outcomes and comply with the federal government’s new regulations on data collection and implementing best practices, Medline Industries, Inc., and Strategic Healthcare Programs (SHP) are together providing a cutting edge solution-based reporting and benchmarking system. The state-of-the-art automated program recognizes specific diagnosis codes in patient records and suggests best-practices supplies and interventions to achieve improved patient outcomes. 

Medline and SHP developed this revolutionary best practices technology to help homecare providers comply with the Centers for Medicare & Medicaid Services (CMS) new Outcome and Assessment Information Set (OASIS-C) and to improve the agencies’ publicly reported scores on Home Health Compare. Patients reap the benefit of better treatment, decreased wound healing time, and reduction in pain. All of these, in turn, improve the providers’ scores while decreasing costs.

“We have developed a program that not only shows home health agencies where their problems exist, but how to fix them with the right products and treatment,” said Mike Lee, president of Medline’s Homecare Division. 

Medline leverages SHP’s real-time reporting capabilities and automated data interfaces with the industry’s software vendors; and then transmits its patient-specific medical supply order data to SHP. Home health agencies receive SHP’s real-time email notifications alerting them to issues that require immediate attention. If the supply orders do not match best practice recommendations, action can be taken. SHP drill-down reports also identify the specific clinician that is delivering care; thereby allowing for targeted education and increased accountability. 

“Our data indicate that proper management of wounds continues to be both a clinical and financial challenge to healthcare providers. Evidence-based best practices programs such as this are the solution to improving the situation. The patient, provider and payer all benefit in this scenario. This is disease management at its best,” said Barbara Rosenblum, Founder and CEO of SHP.

About Medline Industries, Inc.
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and health care systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

About Strategic Healthcare Programs (SHP)
Strategic Healthcare Programs (SHP) is an award-winning innovator in real-time decision support tools that immediately improve patient outcomes and protect financial performance. SHP uses best-of-breed technology and data architecture that enables instant deployment of continuous product enhancements to its clients. SHP is the undisputed industry innovator having pioneered real-time benchmarks, data interfaces, risk modeling, on-demand reporting, pushed alerts, integrated patient satisfaction (HHCAHPS), clinician scorecards, gross profit comparisons, RAC surveillance, telehealth data, and disease management programs. SHP is the industry’s only one-stop source for data, spanning all post-acute business lines. 

TARRYTOWN, NY–(Marketwire – June 30, 2010) –  A new study holds promising evidence that monitoring certain molecules during fetal growth may potentially permit doctors to reverse a cleft palate before birth. Published in the journal Development, researchers at the USC School of Dentistry found that an excess of a specific protein resulted in the formation of a cleft palate. “There are exciting developments on the horizon regarding our understanding of cleft palates,” noted plastic surgeon Dr. Tae Ho Kim of the New York Group for Plastic Surgery in Tarrytown, New York. “Breakthroughs like these could one day help us successfully prevent or treat this condition early on in babies,” Kim continued.

Dr. Kim, a craniofacial and pediatric plastic surgeon, has worked for many years treating patients with craniofacial deformities. He restores the natural symmetry and balance of the human face for those born with complex physical deformities. His work is not limited to cleft palates, as he also works with cases of craniosynostoses, hemangiomas, vascular malformations, jaw deformities, burns and traumatic injuries. In addition to his work as the Chief of Craniofacial and Pediatric Plastic Surgery at the Maria Fareri Children’s Hospital and the Westchester Medical Center, Dr. Kim runs an informational website on cleft palates at www.craniofacialhealing.com.

The protein, sonic hedgehog homolog (SHH), which is regulated by two genes, the Msx1 and the Dlx5, must be maintained within a certain level in order for proper palate formation in a fetus. If the protein is not properly balanced, a cleft palate could form. The Msx1 and Dlx5 genes both encourage and discourage the protein’s growth respectively and are needed for the development of the main facial structures, such as the skull, teeth and the palate.

In the study, originating from the School of Dentistry’s Center for Craniofacial Molecular Biology, fetal mice were purposely bred with an Msx1 deficiency, which suppressed SHH protein growth and promoted the formation of cleft palates. However, when the researchers also suppressed the Dlx5 gene, SHH was expressed and the palate experienced a regrowth. After birth, the palates of the mice were intact, with small differences as compared to the palates of healthy mice. The “regulated” palates, however, functioned as normally as the healthy palates.

Dr. Kim states that cleft palates are one of the most common congenital birth defects in humans. They occur in 1 of every 700 newborns, and are seen more in males than females. The treatment is very complex, taking many years before it is completed. Initial repair is done early, with a subsequent repair happening a year later, then about every 2 to 4 years until the age of 16, if necessary. However, these treatments are not without complications, such as problems with eating or speaking.

Dr. Kim is hopeful. “The proper balance of these genes and their influence on the protein is an exciting concept that could have positive implications on this troubling condition,” he said.

Click here to see all recent news from this company

ALISO VIEJO, CA–(Marketwire – June 30, 2010) –  CNS Response, Inc. (OTCBB: CNSO) today announced that the U.S. Patent and Trademark Office has allowed patent number 77,54,190, Method for Determining Drug Effects Using Quantitative EEG, which extends application of the Company’s Referenced-EEG^® technology platform to improve the performance and efficacy of clinical trials conducted by pharmaceutical companies. The patent will be published July 13, 2010.

“As the costs of discovering and testing new drugs have soared, particularly those in the central nervous system (CNS) class, Referenced-EEG presents new opportunities for the pharmaceutical industry,” said CNS Response CEO George Carpenter. “Our patented methodology can assist pharmaceutical companies in drug discovery, program evaluation, and clinical trial design.”

The contribution of Referenced-EEG has been successfully demonstrated in numerous clinical studies, including the multi-site Depression Efficacy Study completed in 2009. CNS Response submitted a 510(k) for review by the FDA in April 2010.

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

Referenced-EEG was developed by physicians to provide objective, statistical data on patient neurophysiology. In clinical trials, physicians using Referenced-EEG data have consistently achieved superior clinical results compared to physicians using trial and error pharmacotherapy.

To read more about this patented technology, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Click here to see all recent news from this company

LOS ANGELES, CALIFORNIA–(Marketwire – June 30, 2010) – With the passing of the Healthcare Reform Bill, PPACA, healthcare as we know it in the US has changed. Emotions run strong from people supporting it and those who oppose it. Healthcare reform made sweeping changes to the health insurance system and expanded health insurance coverage, but did so without addressing many of the underlying problems within our healthcare system that cause inefficiencies and increased healthcare costs. Such challenges have created a need for a platform to discuss solutions and answer. Renowned world leaders are gathering together National Healthcare Reform Conference in Los Angeles. www.healthcarereformconference.com

“The Patient Protection & Affordable Care Act will change the way many employees receive their coverage and affect the type of health plans workers are allowed to have. Many firms not currently offering coverage will face fines beginning in 2014, while some firms may find their plans do not meet new requirements,” said Devon Herrick, Senior Fellow at the National Center for Policy Analysis. “Conference attendees will learn about their obligations under the new law and how to navigate employers’ and employees’ options,” he added.

Employers, Insurance Companies and Americans will have new challenges to face, as every American is affected differently by healthcare reform. People who are sick will see their health insurance costs go down as healthy Americans may see their prices increase, and older Americans will see their health insurance costs go down as younger Americans may see their prices increase.

“Bringing together a dynamic and diverse group of health care leaders, government officials and industry experts, this Conference will engender thoughtful and timely discussion about how the landscape of health care is changing. I am pleased to be a part of this important opportunity to address the challenges and implications of the health care law for all Americans,” said Therese Vaughan, CEO of the National Association of Insurance Commissioners (NAIC). 

The National Healthcare Reform Conference™ is the first conference in the US to address the problems, challenges and obstacles of implementing Healthcare Reform. The conference, which is sponsored by the Healthcare Reform Magazine, www.healthcarereformmagazine.com, will focus on how healthcare reform affects employers, insurers, insurance agents, healthcare providers and patients and will peel back the onion of the thousands of pages of healthcare reform bill to look at how different aspects of health care reform will really work.

Maureen Ross, Senior Meeting Manager of the National Healthcare Reform Conference stated, “this conference will bring together all the senior leaders in the healthcare sector to share their knowledge and collaborate on how to comply and work under the new healthcare reform law. Some of the top experts in the US will be sharing their knowledge such as the CEO of the National Association of Insurance Commissioners, the Secretary of the Board of Trustees of the American Medical Association, the CEO of the National Association of Health Underwriters, the President of the National Association of Insurance and Financial Advisors, National Center for Policy Analysis, Thomson Reuters, Milliman and other leading experts.”

The National Healthcare Reform Conference™ is part of the Employer Healthcare Congress, www.employerhealthcarecongress.com, which is one of the leading healthcare conferences in the country with a focus on employers.

About Employer Health Congress

The National Healthcare Reform Conference is a stream of Employer Healthcare Congress. Together with four streams 1) Corporate Wellness Conference 2)Voluntary Benefits and Limited Medical Conference 3) Self Funding Employer Healthcare & Workers Compensation Conference and 4) The National Healthcare Reform Conference, The Employer Healthcare Congress is one of the largest US healthcare conferences in the country with up to 2,000 attendees and up to 150 exhibitors and sponsors.

The Employer Healthcare Congress | www.employerhealthcarecongress.com

Corporate Wellness Conference | www.corporatewellnessconference.com

Voluntary Benefits and Limited Medical Conference | www.voluntarybenefitsconference.com

Self Funding Employer HC and Workers Compensation Conference | www.selffundingconference.com

The National Healthcare Reform Conference | www.healthcarereformconference.com

PR & Marketing by ExHealth, Dubai

HOUSTON, TX–(Marketwire – June 30, 2010) –  Independence Day is a national holiday with a multitude of celebrations to commemorate our country’s freedom. The day is marked with traditional family gatherings including parades, picnics and riveting fireworks displays.

But July 4 can be a somber day for members of the military who are facing deployment to military outposts in Iraq and across the Afghan combat zone. The Center of Reproductive Medicine (CORM) maintains that the celebration of Independence Day this year should not exclusively honor those that have fallen in defense of our country, but to also honor those who are currently in harm’s way serving in our military. As a leading Texas fertility clinic, CORM would like to offer men in the military preparing to deploy the opportunity to freeze their sperm at no charge.

CORM has offered sperm freezing since the very first deployment to Iraq in 2003 and will continue to do so until these conflicts come to an end and all of our military have returned home safely.

The process of sperm cryopreservation or freezing is simple and safe in terms of protecting and maintaining fertility potential for the male. The sperm are frozen in liquid nitrogen where the cells will remain unchanged until they are needed. 

“The success rate of conception using frozen sperm is excellent and we are pleased to offer servicemen this option,” said CORM medical director, Vicki Schnell, M.D. “We recognize how difficult deployment can be for couples wanting to start a family and hope that the end result is a safe return and a healthy baby.”

CORM is the only accredited Tricare infertility provider in the Houston Bay Area/Webster and Southeast Beaumont area. Tricare insurance covers infertility diagnostic testing and the cycle management portion of a treatment cycle.

About The Center of Reproductive Medicine
The Center of Reproductive Medicine (CORM), located at 1015 Medical Center Boulevard in Webster, Texas, is a full service, state-of-the-art medical facility dedicated to female and male infertility. CORM has an on-site SurgiCenter, complete diagnostic and laboratory facilities, in-vitro fertilization laboratory and Andrology and Endocrine labs. The highly qualified staff of physicians, nurses, lab technicians and counselors is committed to assisting each patient in a positive and nurturing manner. 

Click here to see all recent news from this company

HERNDON, VA–(Marketwire – June 30, 2010) – Truestone, LLC, a provider of enterprise IT and mission operations solutions to the Federal government, announced today that “Readying Your Infrastructure for EMR” — an article on the steps healthcare providers can take to prepare and implement an electronic medical record (EMR) infrastructure has been featured in the May 2010 issue of Information Week Analytics.

The article, written by John Sankovich, Truestone’s VP of Federal Civilian Services, focuses on making smart technology-ready investment decisions in anticipation of increased demand for medical services and adoption of EMRs. Although the Federal government has created a $17 billion program to reimburse doctors and hospitals for implementing EMR systems, fewer than 10% of providers have taken concrete steps toward digital medical records.

The article provides frameworks for assessing requirements, determining delivery models, selecting hardware vendors and right-sizing server specifications. Sankovich also provides scoping mechanisms to help healthcare providers determine the proper server configuration for the size and scope of their practice. The article is available for purchase at www.analytics.informationweek.com. John Sankovich can be reached at [email protected].

About Truestone
Truestone delivers enterprise IT, cyber security, systems integration and mission operations solutions to the federal government. Founded in 2003, Truestone employs approximately 300 people located in Herndon, VA; Washington, DC; Suffolk, VA; Oakland, CA and at customer sites nationwide. Truestone is a subsidiary of Qivliq, LLC — a NANA company. For more information, visit www.truestonefed.com.